A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis
Phase: PHASE3
Conditions: Lupus Nephritis
Sponsor: Aurinia Pharmaceuticals Inc.

 
This trial will be conducted in compliance with this protocol, ICH GCP and applicable regulatory requirements. 
The information contained in this document is proprietary to Aurinia Pharmaceuticals, Inc. and is not to be copied, disclosed or 
otherwise distributed by an outside authority to any person or persons without the prior written permission of Aurinia. 
 
 
A Randomized, Controlled Double-blind Study Comparing the 
Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice 
Daily) with Placebo in Achieving Renal Response in Subjects 
with Active Lupus Nephritis 
 
Clinical Protocol Number: 
AUR-VCS-2016-01 
 
 
Study Name: 
AURORA (AURinia Orelvo Renal 
Assessments) 1: Aurinia Renal Response in 
Active Lupus with Orelvo (voclosporin) 
 
 
Date: 
04 May 2017 
 
 
Version Number: 
2.0 (Amendment 1) 
 
 
IND Number: 
114577 
 
 
EudraCT Number: 
2016-004045-81 
 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 2 of 114 
 
NAMES AND ADDRESSES 
Lead Investigator 
Name: 
 
 
Address: 
 
 
 
 
Tel: 
 
 
Fax: 
 
 
Email: 
 
 
Sponsor 
Name: 
Aurinia Pharmaceuticals, Inc. 
 
Address: 
#1203 - 4464 Markham Street 
Victoria, BC 
V8Z 7X8 
Canada 
 
Tel: 
 
 
24 Hour: 
 
 
Medical Monitor 
Name: 
 
 
Company: 
Aurinia Pharmaceuticals, Inc. 
 
Address: 
#1203 - 4464 Markham Street 
Victoria, BC 
V8Z 7X8 
Canada 
 
Email: 
 
 
Chief Medical Officer 
Name: 
 
 
Company: 
Aurinia Pharmaceuticals, Inc. 
 
Address: 
#1203 - 4464 Markham Street 
Victoria, BC 
V8Z 7X8 
Canada 
 
Email: 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 3 of 114 
 
Regulatory Representative 
Name: 
 
 
Company: 
Aurinia Pharmaceuticals, Inc. 
 
Address: 
#1203 - 4464 Markham Street 
Victoria, BC 
V8Z 7X8 
Canada 
 
Email: 
 
 
Trial Statistician 
Name: 
 
 
Company: 
Aurinia Pharmaceuticals, Inc. 
 
Address: 
#1203 - 4464 Markham Street 
Victoria, BC 
V8Z 7X8 
Canada 
 
Email: 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 5 of 114 
 
INVESTIGATOR AGREEMENT FORM 
I have read the attached protocol titled: A Randomized, Controlled Double-blind Study 
Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with 
Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis. 
Version Number/Date: 2.0/04 May 2017 
I agree to comply with the current International Council for Harmonisation Guidelines on Good 
Clinical Practice and applicable regulations and guidelines. 
I agree to ensure that financial disclosure statements will be completed by: 
• me (including, if applicable, my spouse (or legal partner) and dependent children); 
• my sub-investigators 
before the start of the study and to report any changes that affect my financial disclosure status 
for up to 1 year after the study is completed. 
I agree to ensure that the confidential information contained in this document will not be used 
for any purpose other than the evaluation or conduct of the clinical investigation without the 
prior written consent of Aurinia Pharmaceuticals Inc. 
Signature by the Investigator on this form documents review, agreement and approval of the 
requirements contained within this protocol. 
 
 
 
Signature 
 
Date (e.g., DD Month Year) 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 6 of 114 
 
SYNOPSIS 
Title: 
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety 
of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal 
Response in Subjects with Active Lupus Nephritis. 
Short Title: 
AURORA (AURinia Orelvo Renal Assessments) 1: Aurinia Renal Response in 
Active Lupus with Voclosporin 
Study Product: 
Orelvo (voclosporin) 
Indication: 
Active lupus nephritis 
Phase: 
3 
Sponsor: 
Aurinia Pharmaceuticals Inc. 
Study Code: 
AUR-VCS-2016-01 
Objectives: 
Primary Objective: 
• To assess the efficacy of Orelvo (voclosporin) compared with placebo in 
achieving renal response after 52 weeks of therapy in subjects with active lupus 
nephritis (LN) 
Secondary Objective: 
• To assess the safety and tolerability of Orelvo over 52 weeks compared with 
placebo in subjects with active LN 
Design: 
Prospective, randomized, placebo-controlled, double-blind, parallel-group, 52-week, 
international, multicenter, 2-arm comparison study of Orelvo versus matching 
placebo. 
Treatment: 
Investigational Treatment: 
Orelvo softgel capsules containing 7.9 mg drug. Approximately 324 subjects will be 
randomized to Orelvo (23.7 mg twice daily (BID)) or matching placebo (162 subjects 
per arm). 
All subjects will receive an initial treatment of intravenous (IV) methylprednisolone, 
followed by a reducing taper of oral corticosteroid. Additionally, all subjects will 
receive background therapy with mycophenolate mofetil (MMF).   
All subjects who complete participation and study treatment through 52 weeks and 
provide consent will have the opportunity to enroll into a continuation study (design 
pending finalization). 
Inclusion Criteria: 
1. Written informed consent before any study-specific procedures are performed. 
2. Male or female subjects with a minimum age of 18 (or legal age of consent 
if >18 years) to 75 years of age, inclusive, at the time of screening (Visit 1). 
3. Previous diagnosis of systemic lupus erythematosus (SLE) according to the 
American College of Rheumatology criteria (1997; see Appendix 5).  
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 7 of 114 
 
 
4. Subjects with evidence of active nephritis, defined as follows: 
Kidney biopsy result within 2 years prior to screening indicating Class III, 
IV-S, IV-G (alone or in combination with Class V), or Class V LN (see 
Appendix 3) with a doubling or greater increase of urine protein creatinine 
ratio (UPCR) within the last 6 months to a minimum of ≥1.5 mg/mg for 
Class III/IV or to a minimum of ≥2 mg/mg for Class V at screening. Biopsy 
results over 6 months prior to screening must be reviewed with a medical 
monitor to confirm eligibility. 
OR 
Kidney biopsy result within 6 months prior to screening indicating Class III, 
IV-S, or IV-G (alone or in combination with Class V) LN with a UPCR of 
≥1.5 mg/mg at screening.  
OR 
Kidney biopsy result within 6 months prior to screening indicating Class V LN 
and a UPCR of ≥2 mg/mg at screening. 
A biopsy can be performed during screening, if not available. The above 
criteria must be fulfilled at baseline. 
5. In the opinion of the Investigator, subject requires high-dose corticosteroids and 
immunosuppressive therapy. 
6. Subject is willing to take oral MMF for the duration of the study, either by 
continuing current MMF therapy or by initiating it on or before the Baseline 
Visit. 
7. Women of childbearing potential must have a negative serum pregnancy test at 
screening and a negative urine pregnancy test at baseline. Two effective forms 
of contraception must be used simultaneously unless abstinence is the chosen 
method. Subjects must use effective contraception during the study (see 
Section 5.4, Adequate/Effective Contraception). 
Exclusion Criteria: 
1. Subjects unable or unwilling to give written informed consent and/or to comply 
with study procedures. 
2. Estimated glomerular filtration rate (eGFR) as calculated by the Chronic Kidney 
Disease Epidemiology Collaboration equation of ≤45 mL/minute/1.73 m2 at 
screening confirmed before randomization. 
3. Currently taking or known need for any of the medications listed in Section 7.8, 
Prohibited Therapy and Concomitant Treatment at screening or during the study. 
This includes prohibited medications prior to screening as specified in 
Section 7.8.1, Prohibited Medications. 
4. Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or 
expected to require dialysis during the study period. 
5. A previous kidney transplant or planned transplant within study treatment 
period. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 8 of 114 
 
6. Any known hypersensitivity or contraindication to MMF, mycophenolic acid, 
cyclosporine, corticosteroids or any components of these drug products. 
7. Current or medical history of: 
• 
Congenital or acquired immunodeficiency. 
• 
In the opinion of the Investigator, clinically significant drug or alcohol abuse 
within 2 years prior to screening. 
• 
Malignancy within 5 years of screening, with the exception of basal and 
squamous cell carcinomas treated by complete excision. Subjects with 
cervical dysplasia that is cervical intraepithelial neoplasia 1, but have been 
treated with conization or loop electrosurgical excision procedure and have 
had a normal repeat Papanicolaou test are allowed. 
• 
Lymphoproliferative disease or previous total lymphoid irradiation. 
• 
Severe viral infection (e.g., cytomegalovirus, hepatitis B virus, hepatitis C 
virus) within 3 months of screening; or known HIV infection. Severe viral 
infection is defined as active disease requiring antiviral therapy. 
• 
Active tuberculosis (TB), or known history of TB/evidence of old TB if not 
taking prophylaxis with isoniazid (see Section 9.2.1, Screening Visit 
Procedures). 
8. Other known clinically significant active medical conditions, such as: 
• 
Severe cardiovascular disease including congestive heart failure, history of 
cardiac dysrhythmia or congenital long QT syndrome. QT interval duration 
corrected for heart rate using method of Fridericia exceeding 480 msec in the 
presence of a normal QRS interval (<110 msec) at time of screening will result 
in exclusion. 
• 
Liver dysfunction (aspartate aminotransferase, alanine aminotransferase, or 
bilirubin ≥2.5 times the upper limit of normal) at screening and, if abnormal at 
screening, then confirmed that the levels have returned to <2.5 times upper 
limit of normal before randomization. 
• 
Chronic obstructive pulmonary disease or asthma requiring oral steroids. 
• 
Bone marrow insufficiency unrelated to active SLE (according to Investigator 
judgment) with white blood cell count <2,500/mm3; absolute neutrophil count 
<1.3 × 103/μL; thrombocytopenia (platelet count <50,000/mm3). 
• 
Active bleeding disorders. 
• 
Current infection requiring IV antibiotics. 
9. Any overlapping autoimmune condition for which the condition or the treatment 
of the condition may affect the study assessments or outcomes (e.g., scleroderma 
with significant pulmonary hypertension; any condition for which additional 
immunosuppression is indicated). Overlapping conditions for which the 
condition or treatment is not expected to affect assessments or outcomes (e.g., 
Sjögren’s syndrome) are not excluded. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 9 of 114 
 
10. No vaccines using live organisms, virus or bacterial, are allowed during 
screening and while taking the study treatment. 
11. Other major physical or psychiatric illness or major traumatic injury within 
6 months prior to screening that may affect study conduct or interfere with study 
assessments or outcome. 
12. Any other medical condition which, in the Investigator’s judgment, may be 
associated with increased risk to the subject or may interfere with study 
assessments or outcomes. 
13. Subjects who are pregnant, breast feeding or, if of childbearing potential, not 
using adequate contraceptive precautions. 
14. Participation in another interventional clinical study within 4 weeks prior to 
screening and/or receipt of investigational drugs within 4 weeks or 5 half-lives 
of the drug (whichever is longer) prior to screening. 
15. Subjects randomized and treated in a previous voclosporin clinical study. 
Primary Endpoint: 
Renal response at Week 52 will be adjudicated by the Clinical Endpoints Committee 
based on the following parameters: 
• 
UPCR of ≤0.5 mg/mg, and 
• 
eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR 
of >20%, and 
• 
Received no rescue medication for LN (see Section 7.8, Prohibited Therapy 
and Concomitant Treatment), and 
• 
Did not receive more than 10 mg prednisone for ≥3 consecutive days or for 
≥7 days in total during Weeks 44 through 52, just prior to the renal response 
assessment. 
Subjects who withdraw from the study prior to the Week 52 assessment will be 
defined as non responders. 
Secondary 
Endpoints: 
• 
Time to UPCR of ≤0.5 mg/mg. 
• 
Partial renal response as defined by 50% reduction from baseline in UPCR 
at Weeks 24 and 52. 
• 
Time to 50% reduction in UPCR from baseline.  
• 
Renal response at Week 52 (based on definition of primary endpoint). 
• 
Duration of UPCR ≤0.5 mg/mg. 
• 
Proportion of subjects experiencing a confirmed >30% decrease from 
baseline in eGFR at each timepoint. 
• 
Change from baseline in UPCR at each time point. 
• 
Change from baseline in serum creatinine, urine protein, and eGFR. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 10 of 114 
 
• 
Change from screening in immunology parameters (complement 3 (C3), C4, 
and anti-double-stranded DNA). 
• 
Renal response with low-dose steroids (defined as renal response in the 
presence of corticosteroids of ≤2.5 mg between Weeks 16 to 24 and 
Weeks 44 to 52). 
• 
Change from baseline in health-related quality of life at Weeks 12, 24, and 
52. 
• 
Health Resource Utilization at Weeks 24 and 52. 
• 
Change from baseline in the Safety of Estrogens in Lupus Erythematosus 
National Assessment - Systemic Lupus Erythematosus Disease Activity 
(SELENA-SLEDAI) Index score at Weeks 24 and 52. 
Procedures: 
See Schedule of Events for full details of protocol required procedures and applicable 
visits (and timings). Subjects who have provided signed and dated informed consent 
will be screened for entry into this study. Baseline proteinuria level is determined by 
a mean of 2 first morning void urine samples taken during the screening period. If a 
subject has not had a kidney biopsy within the required timeframe for study 
eligibility, one may be performed to assess eligibility into the study, provided consent 
is in place and provided the results are received before randomization. Subjects 
meeting the required eligibility criteria will be randomized in a ratio of 1:1 to receive 
either Orelvo (23.7 mg BID) or matching placebo starting on Day 1. All subjects will 
receive initial treatment with 0.5 to 1.0 g IV methylprednisolone. In consultation with 
the Medical Monitor, and if it is in the subject’s best interest, IV methylprednisolone 
may 
be 
started 
during 
the 
screening 
period. 
Subjects 
receiving 
IV 
methylprednisolone in the 3 months prior to screening must be discussed with the 
Medical Monitor prior to initiating further IV methylprednisolone. For subjects who 
are not already taking prescribed MMF prior to randomization, the dosing of MMF 
will start at 500 mg BID for a total daily dose of 1 g/day for the first week, increasing 
to 1 g BID for a total daily dose of 2 g/day for the second and subsequent weeks (i.e., 
beginning on Day 8).  
All subjects will complete dosing through 52 weeks of study treatment. Subjects who 
permanently discontinue study treatment before the Week 52 visit will return for all 
remaining study visits and assessments unless they have withdrawn consent. All 
subjects who complete participation and study treatment through 52 weeks and 
provide consent will have the opportunity to enroll into a continuation study for 
which the details are not yet finalized. 
Sample Size: 
A 2 group continuity corrected Chi square test with a 0.05 two-sided significance 
level will have 80% power to detect the difference between a placebo response rate 
of 20.0% and an Orelvo response rate of 34.4% (odds ratio=2.1) when the sample 
size in each group is 162 (total N=324). While the effect of withdrawals will be 
investigated, subjects withdrawing for any reason will be counted as non-responders 
in the primary analysis and therefore no adjustment of sample size for withdrawals is 
necessary. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 11 of 114 
 
Statistical Methods: 
Analysis: 
All statistical analyses will be undertaken at study closure and will incorporate all 
Week 24 and Week 52 endpoints. 
Populations: 
The efficacy analysis will be based on the intent-to-treat (ITT) principles and will 
consist of all randomized subjects. 
The per-protocol set will be a subset of subjects in the ITT population who do not 
have any major protocol violations (to be defined prior to unblinding). 
The safety analysis set will consist of all subjects who receive at least 1 dose of study 
treatment. 
Methods: 
The primary analysis of the primary endpoint, renal response at Week 52, will be 
conducted on the ITT population. The relative renal response for Orelvo compared 
to placebo will be determined using logistic regression. The logistic regression model 
will include terms for treatment, baseline UPCR, biopsy class, and MMF use at 
baseline. Results of this logistic regression will be displayed as odds ratios and a 
2-sided confidence interval (CI) (Orelvo compared to placebo). The proportion of 
subjects exhibiting renal response at Weeks 24 and 52 will be summarized by 
treatment group. 
The analyses of the secondary endpoints are described below: 
Other binary endpoints will be analyzed in a similar manner to the primary endpoint. 
Endpoints measured as a time-to-event will be displayed using Kaplan-Meier 
methodology. Orelvo will be compared to placebo using a Cox proportional hazard 
model. The model will include terms for treatment and appropriate baseline 
assessments. Median time-to-event along with 2-sided CIs will be displayed. 
Other endpoints will be summarized by visit and differences between baseline and 
on-treatment values at weeks up to and including Week 52 will be analyzed using 
Mixed Effect Model Repeated Measures (MMRM). The MMRM model will include 
terms for treatment, visit, treatment by visit interaction and baseline. Results will be 
expressed as differences between treatment arms (along with associated 95% CI).  
Safety Endpoints: 
Adverse events will be aggregated by System Organ Class and preferred term and 
presented as summary tables. 
Laboratory values (based on results from the central laboratory), vital signs and other 
safety parameters will be summarized by visit as absolute values and change from 
baseline. Laboratory values outside of defined normal ranges will be summarized. 
The impact of withdrawals on primary endpoint will be investigated with a tipping 
point analysis. 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 14 of 114 
 
 
Visit(1) 
Visit 1 
Screening 
Visit 2 
Baseline 
Visit 3 
Visits 
4-8 
Visit 
9 
Visit 10 
Visits 
11-13 
Visit 14 
Visit 15 
End of 
Treatment/ 
Early 
Termination(2) 
Visit 16 
Safety 
Follow-up(3) 
Day/Week 
Day -30 to 
Day -1 
Day 1 
 
Day 2 
Wks 2, 
4, 8, 12, 
16 
±3 days 
Wk 20 
±3 days 
Wk 24 
±10 days 
Wks 30, 
36, 42 
±10 days 
Wk 48 
±10 days 
Wk 52  
±10 days 
Wk 56 
±10 days 
Pregnancy test(12) 
 
 
 
 
 
 
 
 
 
 
AEs(13) 
 
 
 
 
 
 
 
 
 
 
Concomitant 
medications(14) 
 
 
 
 
 
 
 
 
 
 
SELENA-SLEDAI 
 
 
 
 
 
 
 
 
 
 
SF-36 and LupusPro(15) 
 
 
 
(7) 
 
 
 
 
 
 
Healthcare Resource 
Utilization(16) 
 
 
 
 
 
 
 
 
 
 
Dispense study 
treatment/compliance 
 
 
 
 
 
 
 
 
(17) 
 
First dose of study 
treatment (at the study 
site)(18) 
 
 
 
 
 
 
 
 
 
 
MMF dispensing(19) 
 
 
 
 
 
 
 
 
 
 
IV methylprednisolone 
administration(20) 
 
 
 
 
 
 
 
 
 
 
Oral corticosteroid 
tapering(21) 
 
 
 
 
 
 
 
 
 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 15 of 114 
 
 
1 
Unscheduled visits/assessments can be done as needed. Adverse events, concomitant medications and verbal compliance check is needed. 
2 
Subjects who discontinue study treatment or terminate the study early, are to attend an Early Termination Visit and have the assessments listed performed. Subjects who complete study 
treatment will attend the End of Treatment at Week 52 and have the assessments listed performed.  
3 
Subjects who do not enroll into the continuation study will have a follow up safety visit 4 weeks after the last dose of study treatment. 
4 
If a subject has not had a recent kidney biopsy, one may be performed to assess eligibility for the study provided informed consent has been given and results are 
received prior to randomization. If one is performed as part of standard of care after randomization, the results will be recorded in the electronic case report form. 
5 
Complete physical examination at screening, abbreviated examination at all other applicable visits. Height is measured at screening only. 
6 
During the study, and after screening, in the event that a subject is noted to have a QTcF value exceeding 500 msec, or >60 msec more than baseline, the ECG 
will be repeated; see Section 9.1.4.1, Procedures to Manage a Treatment-Emergent Increase in QTc. Electrocardiograms will be recorded digitally after the 
subject has been in a resting, supine position for at least 5 minutes. 
7 
Week 12 only. 
8 
Laboratory assessments will be performed according to the schedule in Section 9.1.1, Laboratory Assessments; subjects must be fasting for at least 8 to 12 hours 
at baseline and end of study/early termination. 
9 
Blood samples will be collected at 0 and 2 hours post dose for pharmacokinetics. 
10 
Two FMV specimens, to be performed and resulted before baseline. 
11 
24-hour urine collection should begin 2 days prior to the scheduled study visit in order not to coincide with the FMV sampling due on the day of the study visit. 
12 
Serum pregnancy test to be evaluated at central laboratory at screening, Week 24, and Week 52; urine pregnancy test will be performed locally at all other 
applicable visits. 
13 
Adverse events will be recorded after the subject signs the ICF; AEs which occur during screening or prior to the first dose of study treatment will not be 
considered TEAEs. 
14 
Concomitant medications include all herbal medicines and supplements taken by the subject. 
15 
For details on HRQoL assessments, see Section 9.3.1, Health-related Quality of Life Assessments (HRQoL). 
16 
For details on Healthcare Resource Utilization, see Section 9.3.2, Healthcare Resource Utilization Assessment. 
17 
Compliance only. 
18 All scheduled procedures must be done prior to first dose, including IV methylprednisolone and MMF. 
19 
For subjects not on MMF during screening, will start receiving MMF therapy at the Baseline Visit and return for local complete blood count assessments at 
Weeks 1 and 3 after randomization (see Section 7 2 2 3, Mycophenolate Mofetil (Background Therapy)). 
20 
IV methylprednisolone administered 0.5 g on baseline and Day 2. If IV corticosteroids must be administered during screening then the FMV urine specimens 
will be collected prior to the infusion (see Section 7.2.2.2, Corticosteroids). 
21 
See Section 7.2.2.2, Corticosteroids. 
Notes: Subjects who discontinue therapy will attend their regularly scheduled study visits to the end of the study. Subjects who withdraw consent and terminate the 
study early or discontinue treatment early should be advised to attend both Visit 15 and the Safety Follow up Visit (Visit 16). 
Abbreviations: AE=adverse event; BP=blood pressure; CBC=complete blood count; ECG=electrocardiogram; FMV=first morning void; HRQoL=health-related quality of life; IV=intravenous; 
LN=lupus nephritis; MMF=mycophenolate mofetil; QTcF=QT interval duration corrected for heart rate using method of Fridericia; SAE=serious adverse event; SELENA-SLEDAI=Safety of 
Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index; SLE=systemic lupus erythematosus. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 16 of 114 
 
TABLE OF CONTENTS 
Page 
NAMES AND ADDRESSES ...................................................................................................2 
DECLARATION OF SPONSOR ...........................................................................................4 
INVESTIGATOR AGREEMENT FORM ............................................................................5 
SYNOPSIS ................................................................................................................................6 
SCHEMA ................................................................................................................................12 
AUR-VCS-2016-01 SCHEDULE OF EVENTS ..................................................................13 
TABLE OF CONTENTS ......................................................................................................16 
LIST OF TABLES .................................................................................................................21 
LIST OF APPENDICES .......................................................................................................21 
LIST OF ABBREVIATIONS ...............................................................................................22 
1. 
INTRODUCTION AND BACKGROUND ..................................................................25 
1.1 
Background of the Disease and Treatment Options – Lupus Nephritis .......................25 
1.1.1 
Limitations of Current Treatment .............................................................................25 
1.2 
Rationale for the Use of Calcineurin Inhibitors in Lupus Nephritis ............................27 
1.2.1 
Mechanism of Action................................................................................................27 
1.2.2 
Use of Immunosuppression in Lupus Nephritis .......................................................27 
1.2.3 
Clinical Studies of Calcineurin Inhibitors in Lupus Nephritis .................................28 
1.2.4 
Voclosporin ...............................................................................................................29 
1.2.4.1 
Pharmacokinetic Considerations ............................................................................29 
1.2.4.2 
Lupus Nephritis Clinical Development .................................................................30 
1.2.5 
Potential Toxicities ...................................................................................................31 
2. 
RATIONALE .................................................................................................................33 
2.1 
Dose Rationale .............................................................................................................33 
3. 
STUDY OBJECTIVES ..................................................................................................35 
3.1 
Primary Objective ........................................................................................................35 
3.2 
Secondary Objective ....................................................................................................35 
3.3 
Endpoints .....................................................................................................................35 
3.3.1 
Primary Endpoint ......................................................................................................35 
3.3.2 
Secondary Endpoints ................................................................................................35 
3.3.2.1 
Key Secondary Endpoints ......................................................................................35 
3.3.2.2 
Other Secondary Endpoints ...................................................................................36 
4. 
INVESTIGATIONAL PLAN .......................................................................................37 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 17 of 114 
 
4.1 
Overall Study Design ...................................................................................................37 
4.2 
Duration of Subject Participation and Study ...............................................................37 
5. 
SELECTION, 
WITHDRAWAL 
OF 
SUBJECTS 
AND 
PERMANENT 
DISCONTINUATION OF DRUG ................................................................................38 
5.1 
Number of Subjects......................................................................................................38 
5.2 
Inclusion Criteria .........................................................................................................38 
5.3 
Exclusion Criteria ........................................................................................................39 
5.4 
Adequate/Effective Contraception ...............................................................................41 
5.5 
Withdrawal of Subjects ................................................................................................42 
5.6 
Discontinuation of Study Treatment ............................................................................42 
5.6.1 
Discontinuation from Study Treatment Due to Early Non-response to Therapy .....42 
5.6.2 
Discontinuation of Study Treatment Due to an Adverse Event................................43 
6. 
RANDOMIZATION, BLINDING AND UNBLINDING PROCEDURES ..............44 
6.1 
Randomization .............................................................................................................44 
6.2 
Blinding........................................................................................................................44 
6.3 
Unblinding ...................................................................................................................44 
7. 
STUDY TREATMENTS ...............................................................................................46 
7.1 
Dosage Forms/Formulation .........................................................................................46 
7.1.1 
Orelvo– Study Treatment..........................................................................................46 
7.1.2 
Placebo Control.........................................................................................................46 
7.1.3 
Background Therapy.................................................................................................46 
7.1.3.1 
Mycophenolate Mofetil ..........................................................................................46 
7.1.3.2 
Corticosteroids .......................................................................................................46 
7.2 
Drug Dosage and Administration ................................................................................46 
7.2.1 
Treatment Arms ........................................................................................................46 
7.2.2 
Dosing Guidelines.....................................................................................................47 
7.2.2.1 
Orelvo/Placebo – Study Treatment ........................................................................47 
7.2.2.2 
Corticosteroids .......................................................................................................47 
7.2.2.3 
Mycophenolate Mofetil (Background Therapy) ....................................................49 
7.3 
Package and Labeling ..................................................................................................50 
7.4 
Study Treatment Allocation .........................................................................................51 
7.5 
Site Supply, Storage, Accountability ...........................................................................51 
7.5.1 
Site Supply ................................................................................................................51 
7.5.2 
Storage ......................................................................................................................51 
7.5.3 
Accountability ...........................................................................................................51 
7.6 
Orelvo/Placebo Dose Modification..............................................................................52 
7.6.1 
Deterioration in Renal Function ...............................................................................52 
7.6.1.1 
Decrease in eGFR >30% and eGFR <60 mL/min/1.73 m2 ....................................52 
7.6.1.2 
Decrease in eGFR ≤30% and eGFR <60 mL/min/1.73 m2 ....................................53 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 18 of 114 
 
7.6.1.3 
Recovery of eGFR .................................................................................................53 
7.7 
Procedures for Overdose ..............................................................................................53 
7.8 
Prohibited Therapy and Concomitant Treatment .........................................................53 
7.8.1 
Prohibited Medications .............................................................................................54 
7.8.2 
Allowed Concomitant Medications ..........................................................................55 
7.9 
Increased Blood Pressure .............................................................................................55 
8. 
RISKS/PRECAUTIONS ...............................................................................................56 
9. 
STUDY PROCEDURES ...............................................................................................57 
9.1 
Description of Study Assessments ...............................................................................57 
9.1.1 
Laboratory Assessments ...........................................................................................57 
9.1.1.1 
Evaluation of Biomarkers ......................................................................................59 
9.1.2 
Physical Examinations ..............................................................................................59 
9.1.3 
Vital Signs.................................................................................................................60 
9.1.3.1 
Blood Pressure Management .................................................................................60 
9.1.4 
Standard 12-lead Electrocardiogram ........................................................................60 
9.1.4.1 
Procedures to Manage a Treatment-Emergent Increase in QTc ............................61 
9.1.5 
Lupus Disease Activity Assessments .......................................................................61 
9.1.6 
Orelvo Pharmacokinetics ..........................................................................................61 
9.2 
Schedule of Assessments .............................................................................................61 
9.2.1 
Screening Visit Procedures .......................................................................................62 
9.2.2 
Treatment Procedures ...............................................................................................62 
9.2.3 
End of Study (or Early Discontinuation) Procedures ...............................................64 
9.2.4 
Follow-up Procedures ...............................................................................................65 
9.2.5 
Unscheduled Visit .....................................................................................................65 
9.3 
Study Specific Assessment Procedures .......................................................................66 
9.3.1 
Health-related Quality of Life Assessments (HRQoL) .............................................66 
9.3.1.1 
Short Form Health Survey (SF-36) ........................................................................66 
9.3.1.2 
LupusPRO ..............................................................................................................66 
9.3.2 
Healthcare Resource Utilization Assessment ...........................................................66 
10. EVALUATION, RECORDING AND REPORTING OF AES AND SAES .............67 
10.1 
Definitions....................................................................................................................67 
10.1.1 
Adverse Event ...........................................................................................................67 
10.1.2 
Adverse Drug Reaction .............................................................................................67 
10.1.3 
Serious Adverse Event ..............................................................................................67 
10.1.4 
Suspected Unexpected Serious Adverse Reaction....................................................68 
10.2 
Adverse Event Descriptors ..........................................................................................68 
10.2.1 
Intensity/Severity Categorization .............................................................................68 
10.2.2 
Causal Relationship Categorization ..........................................................................69 
10.2.3 
Outcome Categorization ...........................................................................................69 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 19 of 114 
 
10.2.4 
Symptoms of the Disease Under Study ....................................................................70 
10.2.5 
Clinical Laboratory Evaluations ...............................................................................70 
10.2.6 
Abuse, Misuse, Overdose and Medication Error ......................................................70 
10.3 
Reporting Procedure for AEs, SAEs, and Pregnancy ..................................................70 
10.3.1 
Adverse Events .........................................................................................................70 
10.3.2 
Serious Adverse Events ............................................................................................71 
10.3.3 
Pregnancy..................................................................................................................73 
11. CLINICAL ENDPOINTS COMMITTEE ..................................................................74 
12. DATA AND SAFETY MONITORING BOARD PROCEDURES ...........................75 
13. STATISTICAL ANALYSIS .........................................................................................76 
13.1 
Statistical Methods .......................................................................................................76 
13.2 
Sample Size and Power Calculations ...........................................................................76 
13.3 
Populations ...................................................................................................................76 
13.3.1 
Intent-to-Treat Set .....................................................................................................76 
13.3.2 
Safety Set ..................................................................................................................77 
13.3.3 
Per-protocol Set ........................................................................................................77 
13.4 
Background and Demographic Characteristics ............................................................77 
13.5 
Study Treatment ...........................................................................................................77 
13.6 
Concomitant Therapy...................................................................................................77 
13.7 
Efficacy Evaluations ....................................................................................................77 
13.7.1 
Primary Endpoint ......................................................................................................77 
13.7.2 
Secondary Endpoints ................................................................................................78 
13.7.2.1 
Key Secondary Endpoints ......................................................................................78 
13.7.2.2 
Other Secondary Endpoints ...................................................................................78 
13.8 
Statistical and Analytical Methods ..............................................................................79 
13.8.1 
Primary Efficacy Analysis ........................................................................................79 
13.8.2 
Sensitivity Analyses ..................................................................................................79 
13.8.3 
Secondary Efficacy Analysis ....................................................................................79 
13.8.3.1 
Response Endpoints ...............................................................................................79 
13.8.3.2 
Time to Endpoints ..................................................................................................80 
13.8.3.3 
Change from Baseline Endpoints...........................................................................80 
13.8.3.4 
Health Resource Utilization ...................................................................................81 
13.8.4 
Multiplicity ...............................................................................................................81 
13.9 
Safety Evaluations .......................................................................................................81 
13.10 Interim Analyses ..........................................................................................................82 
13.11 Other Evaluations.........................................................................................................82 
13.11.1 Pharmacokinetics ......................................................................................................82 
14. ETHICAL CONDUCT OF THE STUDY ...................................................................83 
14.1 
Informed Consent.........................................................................................................83 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 20 of 114 
 
14.2 
Institutional Review Board or EC/IEC ........................................................................83 
15. QUALITY CONTROL AND QUALITY ASSURANCE ...........................................84 
16. ADMINISTRATIVE PROCEDURES .........................................................................85 
16.1 
Sponsor’s Responsibilities ...........................................................................................85 
16.1.1 
Study Supplies ..........................................................................................................85 
16.1.2 
Insurance ...................................................................................................................85 
16.1.3 
Study Monitoring ......................................................................................................85 
16.2 
Investigator’s Responsibilities .....................................................................................86 
16.2.1 
Reporting and Recording of Data .............................................................................86 
16.2.2 
Investigator Training.................................................................................................86 
16.2.3 
Source Documentation ..............................................................................................86 
17. PROCEDURE FOR MODIFICATION OF PROTOCOL OR PREMATURE 
TERMINATION OF THE STUDY .............................................................................88 
17.1 
Protocol Waivers, Deviations and Violations ..............................................................88 
17.2 
Study Termination .......................................................................................................88 
18. POLICY FOR PUBLICATION AND PRESENTATION OF DATA ......................89 
19. REFERENCES ...............................................................................................................90 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 21 of 114 
 
LIST OF TABLES 
Page 
Table 1 
Dosing Schedule for IV Methylprednisolone and Daily Oral 
Prednisone (mg) ...............................................................................................49 
Table 2 
Review of Laboratory Assessments .................................................................57 
Table 3 
Orelvo Response Rates Required to Maintain a Minimum 80% Power ..........76 
 
LIST OF APPENDICES 
Page 
Appendix 1 
Drug Therapy for the Treatment of Hypertension ...........................................93 
Appendix 2 
Measurement of Blood Pressure ......................................................................94 
Appendix 3 
International Society of Nephrology and the Renal Pathology Society 
(ISN/RPS) 2003 Classification of Lupus Nephritis .........................................95 
Appendix 4 
Conversion Table for Oral Corticosteroids ......................................................97 
Appendix 5 
1997 Update of the 1982 American College of Rheumatology Revised Criteria 
for the Classification of Systemic Lupus Erythematosus ................................98 
Appendix 6 
Systemic Lupus Erythematosus Disease Activity Measure 
(SELENA-SLEDAI) ......................................................................................100 
Appendix 7 
Expanded List of Allowed Concomitant Medications ...................................102 
Appendix 8 
Summary of Treatment and Food Restrictions ..............................................104 
Appendix 9 
Short Form Health Survey (SF-36) HRQoL Assessment ..............................105 
Appendix 10 LupusPRO (v1.7) HRQoL Assessment .........................................................111 
 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 22 of 114 
 
LIST OF ABBREVIATIONS 
ACE 
Angiotensin converting enzyme 
ADR 
Adverse drug reaction 
AE 
Adverse event 
ALMS 
Aspreva Lupus Management Study 
ANC 
Absolute neutrophil count 
ARB 
Angiotensin receptor blocker 
AUC0-12 
Area under the curve between 0 and 12 hours 
AUC0-24 
Area under the curve between 0 and 24 hours 
AURA-LV 
Aurinia Urinary protein Reduction Active – Lupus with 
Voclosporin 
AURION 
Aurinia early Urinary protein ReductION Predicts Response 
AURORA 
AURinia Orelvo Renal Assessments 
Aurinia 
Aurinia Pharmaceuticals Inc. 
AZA 
Azathioprine 
BID 
Twice daily 
BP 
Blood pressure 
C3 / C4 
Complement 3 / complement 4 
CEC 
Clinical Endpoints Committee 
CI 
Confidence interval 
CKD-EPI 
Chronic Kidney Disease Epidemiology Collaboration 
Cmax 
Maximum concentration 
CNI 
Calcineurin inhibitor 
CsA 
Cyclosporine A 
CYP3A4/5 
Cytochrome P450 3A4/5 
DMC 
Data Monitoring Committee 
dsDNA 
Double-stranded deoxyribonucleic acid 
DSMB 
Data and Safety Monitoring Board 
EC 
Ethics Committee 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 23 of 114 
 
EDC 
Electronic data capture 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eGFR 
Estimated glomerular filtration rate 
ESRD 
End-stage renal disease 
FAS 
Full analysis set 
GCP 
Good Clinical Practice 
GI 
Gastrointestinal 
GMP 
Good Manufacturing Practice 
HCP 
Health care professional 
HIV 
Human immunodeficiency virus 
HR 
Heart rate 
HRQoL 
Health-related quality of life 
IB 
Investigator’s Brochure 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
ITT 
Intent-to-treat 
IV 
Intravenous 
IVC 
Intravenous cyclophosphamide 
IWRS 
Interactive web response system 
LN 
Lupus nephritis 
MMF 
Mycophenolate mofetil 
MMRM 
Mixed Effect Model Repeated Measures 
NSAID 
Non-steroidal anti-inflammatory drug 
OR 
Odds ratio 
Orelvo 
Voclosporin (for Phase 3 lupus nephritis indication) 
P-gp 
P-glycoprotein 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 24 of 114 
 
PK 
Pharmacokinetic 
QTc 
Corrected QT interval 
QTcF 
QT interval duration corrected for heart rate using method of 
Fridericia 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SELENA 
Safety of Estrogens in Lupus Erythematosus National Assessment 
SLE 
Systemic lupus erythematosus 
SLEDAI 
Systemic Lupus Erythematosus Disease Activity Index 
t1/2 
Terminal elimination half-life 
TB 
Tuberculosis 
TEAE 
Treatment-emergent adverse event 
UPCR 
Urine protein creatinine ratio 
 
 
WHO 
World Health Organization 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 25 of 114 
 
1. INTRODUCTION AND BACKGROUND 
1.1 
Background of the Disease and Treatment Options – Lupus 
Nephritis 
Lupus nephritis (LN) is the most common serious manifestation of systemic lupus 
erythematosus (SLE). Lupus nephritis is divided into different classes according to the level of 
treatment required, using a classification system for renal biopsy pathology originally 
developed by the World Health Organization (WHO). The classification of LN has evolved 
and the “International Society of Nephrology/Renal Pathology Society 2003 Classification of 
Lupus Nephritis” is now widely used and has a higher level of inter-observer reproducibility 
than the original classification (see Appendix 3). For subjects with Class III, IV (proliferative), 
or V (membranous), or combinations of these forms of LN, the standard of care is treatment 
with corticosteroids and immunosuppressive therapy. 
Lupus nephritis manifests as diverse patterns of immune complex-mediated renal disease 
affecting glomerular, tubulointerstitial, and vascular compartments. It can lead to permanent 
and irreversible tissue damage within the kidney, resulting in end-stage renal disease (ESRD), 
and thus making LN a serious and potentially life-threatening condition. In subjects with LN, 
renal damage results in proteinuria and/or hematuria and a decrease in renal function as 
evidenced by reduced creatinine clearance and estimated glomerular filtration rate (eGFR), and 
increased serum creatinine levels. 
In LN as in other serious renal diseases, the main clinical outcomes are progression to ESRD 
(i.e., the need for long-term dialysis or transplantation) and death. The current standard of care 
for LN, corticosteroids and immunosuppressants, has improved the prognosis of the disease 
considerably. Incidence rates of ESRD in LN, however, appear to have been stable over recent 
years, possibly reflecting the limits of effectiveness of current treatments or lack of adherence 
to treatments by subjects. The most recent studies have reported 10-year survival rates of over 
90% and, although the overall risk of developing ESRD in subjects with LN is approximately 
15%, the 5-year risk of developing ESRD has been found to be as low as 5% [1]. Recently, 
10-year follow-up data of LN subjects treated with intravenous cyclophosphamide (IVC) for 
active disease followed by maintenance treatment with azathioprine (AZA) found rates of 
ESRD to be approximately 7% [2]. 
1.1.1 Limitations of Current Treatment 
The current treatment paradigm for LN includes 2 goals, based on the severity of disease. The 
first goal of treatment in subjects with active LN is intended to bring the disease under control 
as quickly as possible to limit the potential for extensive renal scarring or loss of life. This 
phase of treatment is particularly critical for those subjects at highest risk for ESRD (i.e., 
subjects with clinical or laboratory indicators of active nephritis, such as biopsy evidence of 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 26 of 114 
 
proliferative nephritis, active urinary sediment, elevated serum creatinine, and/or proteinuria). 
In subjects with severe LN, the achievement of complete or partial remission, as demonstrated 
by stabilization or improvement in renal function, improvement in proteinuria, and 
normalization of active urinary sediment, has been shown to be associated with better patient 
and renal survival. Treatment of active LN (i.e., induction treatment) typically consists of high 
doses of both corticosteroids and immunosuppressants. 
The second goal of treatment, after the patient successfully responds to treatment, is to 
maintain remission by preventing renal flares and any resulting deterioration in renal function. 
In this second phase of treatment, lower doses of both corticosteroids and immunosuppressants 
are used. 
Corticosteroids are the cornerstone of treatment in SLE, and have been the standard since the 
1950s to treat both renal and non-renal manifestations. Intravenous (IV) steroid pulse therapy 
is widely used to rapidly treat relapsing LN, but does not provide long-term management. Oral 
corticosteroids taken for prolonged periods and at high doses are often needed, but have 
potentially severe, and at times irreversible adverse effects including risk of infection, 
hyperlipidemia, hypertension, osteoporosis, diabetes, and accelerated atherosclerosis. 
Induction treatment recommendations advocate the use of immunosuppressants in conjunction 
with high-dose oral corticosteroids, to enable a rapid taper to a lower maintenance dose of 
steroids. Steroid-sparing therapies are needed in order to treat disease activity and also 
minimize cumulative and high-dose steroid exposure. 
Intravenous cyclophosphamide, while classically considered the standard of care for induction 
therapy, is still associated with significant potentially life-threatening toxicities, such as the 
increased risk of severe infections including sepsis, malignancy, and major morbidity, such as 
permanent gonadal failure. 
Recent studies have shown that induction treatment with mycophenolate mofetil (MMF) has 
similar efficacy to that of IVC. The authors of a recent meta-analysis concluded that MMF is 
as efficacious as IVC and is not associated with the risk of infertility, which is a significant 
toxicity of IVC in this patient population [3]. In the Aspreva Lupus Management Study 
(ALMS), a comparison of MMF and IVC in the treatment of active LN, 50.4% subjects with 
active LN entering the study had nephrotic-range proteinuria (>3 g/day) [4]. Intravenous 
cyclophosphamide and MMF reduced proteinuria to a similar extent. However, even after 
24 weeks of therapy with either MMF or IVC in the setting of a clinical study, subjects had 
substantial residual proteinuria. At the end of 24 weeks of therapy, normal (<500 mg/24 hours) 
protein excretion levels were observed in only 27% of subjects who received IVC and 23.8% 
of subjects who received MMF [5]. The findings from ALMS indicate that there exists a 
substantial unmet medical need for more effective treatments for active LN with heavy 
proteinuria. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 27 of 114 
 
The importance of proteinuria and reduction of proteinuria as prognostic factors for renal 
flares, ESRD and death in subjects with LN is well documented. Proteinuria in itself is related 
to progression of renal disease through effects on the glomerulus and tubulointerstitium [6]. In 
observational studies, proteinuria has been shown to be a predictor of adverse renal outcomes, 
cardiovascular disease, and mortality in subjects with non-diabetic proteinuric 
nephropathies [7]. 
1.2 
Rationale for the Use of Calcineurin Inhibitors in Lupus Nephritis 
1.2.1 Mechanism of Action 
Calcineurin inhibitors (CNIs) are a class of immunosuppressants which reversibly inhibit 
immunocompetent lymphocytes, particularly T-lymphocytes in the G0 and G1 phase of the 
cell-cycle, and also reversibly inhibit the production and release of lymphokines. Voclosporin, 
a CNI, mediates its suppressive effects by binding to an ubiquitous intracellular protein 
cyclophilin. This complex, in turn, inhibits the calcium- and calmodulin-dependent 
serine/threonine phosphatase activity of the enzyme calcineurin. Calcineurin inhibition then 
prevents the activation of various transcription factors necessary for the induction of cytokine 
genes during T-cell activation, such as interleukin-2, interleukin-4, tumor necrosis factor-α, 
granulocyte-macrophage colony stimulating factor, and interferon-γ. 
1.2.2 Use of Immunosuppression in Lupus Nephritis 
Calcineurin inhibitors are standard treatment to prevent acute rejection in subjects who have 
received transplants. Since the development of cyclosporine in the early 1980s, standard 
immunosuppression regimens to prevent rejection post-transplantation have included steroids 
and a CNI; more recently other immunosuppressants, such as MMF, have been added to 
standard therapy. The rationale for use of CNIs in autoimmune diseases include potent effects 
on T-cell activation and immunomodulatory effects. AT-cell mediated immune response is an 
important feature of the pathogenesis of many of these diseases, including LN. Calcineurin 
inhibitors also have specific anti-proteinuric effects. The podocyte is a key cell in the 
glomerular capillary wall that maintains the integrity of the filtration barrier and prevents the 
development of proteinuria in healthy individuals, while being the primary target of injury in 
proteinuric kidney disease. Podocyte injury is an important factor in the progression of LN. It 
typically occurs due to immune complex deposition but may also occur in the absence of this 
histologic feature [8]. Podocyte function depends on a complex and unique structure that, in 
turn, depends on a tightly regulated actin cytoskeleton. Synaptopodin acts as a key stabilizer 
of the actin cytoskeleton in podocytes. When synaptopodin is phosphorylated, it binds to 
another protein, 14-3-3, and is thus protected from degradation. Calcineurin dephosphorylates 
synaptopodin allowing its degradation, thus promoting proteinuria by destabilization of the 
podocyte actin cytoskeleton. Expression of activated calcineurin in podocytes leads to 
proteinuria. By inhibiting activated calcineurin, tacrolimus thus exerts a specific 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 28 of 114 
 
anti-proteinuric effect by preventing the degradation of the podocyte-stabilizing protein 
synaptopodin. Taken together, these data suggest that the anti-proteinuric effects of CNIs may 
be explained by their direct effect on the podocyte actin cytoskeleton as well as 
immunomodulatory effects on T-lymphocytes [9]. 
1.2.3 Clinical Studies of Calcineurin Inhibitors in Lupus Nephritis 
Bao et al, 2008 [10] performed an open-label study in 40 subjects with Class V+IV LN. 
Subjects were randomized to either IVC and prednisolone or “multi-target therapy” with MMF 
plus tacrolimus (4 mg/day) and prednisolone. In the multi-target group, 50% achieved 
complete remission compared with 5% in the standard IVC group at 6 months. Estimated 
glomerular filtration rate normalized in both groups, but there was a significantly larger 
reduction in proteinuria in the multi-target therapy group.  
Miyasaka et al, 2009 [11] evaluated the efficacy and safety of tacrolimus in 63 subjects 
receiving glucocorticoid therapy for LN in a double-blind, placebo-controlled, randomized 
trial. Subjects with persistent nephritis requiring 10 mg/day prednisone were randomized to 
receive 28 weeks of treatment with tacrolimus (3 mg/day) or placebo. There was a statistically 
significant improvement in the primary endpoint, the Lupus Nephritis Disease Activity Index, 
in the tacrolimus group compared to the placebo group. Daily urinary protein excretion (the 
percentage of subjects with urine protein <0.3 g/day at the final evaluation) also showed a 
significant decrease in the tacrolimus group. However, measures of glucose intolerance were 
more frequent in tacrolimus-treated subjects. The authors concluded that tacrolimus should be 
considered one of the options to treat LN. On the basis of the results of this study, tacrolimus 
was approved for the treatment of LN in Japan. 
In an observational study conducted by Cortes-Hernandez et al, 2010 [12], 70 subjects who 
had received MMF as continuous therapy were followed over a 5-year period. Tacrolimus was 
added as rescue therapy in 17 subjects who were treatment failures or had renal flares on 
treatment with MMF. The authors reported a significant reduction in proteinuria at 3 months, 
and after 2 years of follow-up, it was concluded that tacrolimus was a safe and effective 
treatment for MMF non-responsive cases. 
Several smaller pilot studies and case series in subjects with LN, including subjects with 
membranous nephropathy, have suggested a treatment benefit of tacrolimus with or without 
MMF [13-19]. 
The available data suggest a plausible mechanism of action by which CNIs may provide 
treatment benefits in LN. The clinical evidence is suggestive of improvement in measures of 
response in active LN and improvement in extrarenal manifestations of SLE and immunologic 
parameters. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 29 of 114 
 
1.2.4 Voclosporin 
Voclosporin is a next-generation CNI developed for the treatment of autoimmune diseases and 
for use in the prevention of organ graft rejection. Voclosporin is structurally similar to 
cyclosporine A (CsA) except for a novel modification of a functional group on the amino acid 1 
residue of the molecule. This alteration has changed the binding of voclosporin to calcineurin 
leading to a 3- to 5-fold increase in potency when compared to CsA. This modification has 
also shifted metabolism away from amino acid 1, the major site of metabolism for CsA, thus 
altering the metabolic profile. This in turn has led to faster elimination of metabolites resulting 
in lower measured metabolite exposure as compared to CsA. The combination of increased 
potency and decreased measured metabolite exposure, for voclosporin as compared to CsA, 
has led to better pharmacokinetic (PK)/ pharmacodynamic predictability. 
During the development of this investigational product the legacy names of voclosporin, VCS, 
 are referenced in discussions related to historical usage. However, for the LN Phase 3 
clinical development program, the name of the investigational product will be referred to as 
Orelvo, the proposed trade name. These legacy names should all be considered interchangeable 
unless specifically identified as different. 
Prior to the LN clinical development program, approximately 2,200 subjects received 
investigational products containing voclosporin in 14 Phase 1 and 10 Phase 2/3 clinical studies 
in the indications of transplant rejection, psoriasis and non-infectious uveitis. Detailed data for 
these clinical studies are presented in the Investigator’s Brochure (IB).  
1.2.4.1 Pharmacokinetic Considerations 
Voclosporin approximates linear multiexponential PKs. Exposure to voclosporin was 
dose-related with maximum concentrations occurring ≤2 hours with a terminal elimination 
half-life (t1/2) of ≥30 hours. Drug accumulation was minor with accumulation factors of 
approximately 2 hours after twice daily (BID) dosing. Administration of voclosporin oral 
solution with either low- or high-fat meals decreased both the rate and extent of absorption 
which appeared to be related to the fat content of the meal. It is therefore recommended that 
Orelvo (voclosporin) be administered on an empty stomach to ensure adequate absorption. 
Voclosporin has been shown to be a substrate of cytochrome P450 3A4/5 (CYP3A4/5). 
Concomitant administration of ketoconazole, a strong CYP3A4/5 inhibitor, led to a 6-fold 
increase in maximum concentration (Cmax) and an 18-fold increase in area under the curve 
between 0 and 12 hours (AUC0-12) for voclosporin. Concomitant administration of rifampin, 
an inducer of CYP3A4/5, resulted in a decrease in exposure to voclosporin. Maximum 
concentration decreased approximately 70%, the area under the concentration curve decreased 
approximately 90%, and t1/2 decreased 85%. Consequently, both ketoconazole and rifampin 
are contraindicated with Orelvo (voclosporin). Concomitant administration of voclosporin and 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 30 of 114 
 
midazolam, a model substrate of CYP3A4/5 and potential inhibitor of CYP3A4/5, did not 
result in statistically significant changes in the rate or extent of exposure to midazolam or 
α-hydroxy-midazolam. 
Voclosporin is both a substrate for and an inhibitor of P-glycoprotein (P-gp). Concomitant 
administration of verapamil, a known inhibitor of P-gp, demonstrated an approximate 3-fold 
increase in Cmax and AUC0-12 of voclosporin. Concomitant administration of digoxin, a P-gp 
substrate, resulted in statistically significant increases in digoxin Cmax and area under the curve 
between 0 and 24 hours (AUC0-24) and a decrease in clearance. Therefore concomitant 
administration of P-gp substrates with voclosporin would be expected to result in increased 
exposure to the substrate. Clinicians are advised to consider the benefit/risk of concomitant 
P-gp substrate drugs carefully. 
1.2.4.2 Lupus Nephritis Clinical Development 
The AURA-LV study (Protocol AUR-VCS-2012-01) is a randomized, controlled, 
double-blind Phase 2 study comparing the efficacy and safety of voclosporin (23.7 mg BID or 
39.5 mg BID) with placebo in achieving remission in patients with active LN. The duration of 
the study is 48 weeks and is ongoing. All patients received background therapy with MMF and 
corticosteroid taper. The primary endpoint of complete remission was defined as: urine protein 
creatinine ratio (UPCR) of ≤0.5 mg/mg at 24 weeks (using first morning void) and eGFR 
≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of ≥20%. In addition, 
patients could not receive rescue medications for LN (defined as >10 mg prednisone/day 
for >3 consecutive days or >7 days total from Weeks 16-24) to be considered for complete 
remission.  
A total of 265 subjects were randomized into the AURA-LV study. The 24-week primary 
endpoint assessment for the AURA-LV clinical study demonstrated that the groups were 
generally well balanced for age, gender and race, with a trend to higher proteinuria and lower 
eGFR data in the low-dose voclosporin arm. The low dose achieved a statistically significant 
benefit over placebo for the primary efficacy assessment of complete remission at 24 weeks 
(odds ratio (OR) [95% CI] = 2.03, [1.01, 4.05], p=0.045), without a statistically significant 
improvement seen in the high dose. The results were confirmed by 24 hour urine collections 
(p=0.047). Both the low- and high-dose voclosporin were statistically superior to placebo in 
partial remission, time to complete remission, and time to partial remission. A mean reduction 
in serum creatinine was seen in both arms (0.2 mg/dL low, 0.1 high; p<0.001). In the 
voclosporin groups, eGFR fell by a median of 8-9 mL/min by Week 4 and then stabilized over 
the course of the study. Blood pressure did not vary by group. The correlation of 24-hour urine 
protein and using the first morning void was assessed from the results of the AURA-LV study 
demonstrating a high degree of correlation (Pearson Correlation Coefficient = 0.92). 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 31 of 114 
 
Over 90% of subjects experienced at least 1 adverse event (AE); the most common being 
infectious disease (56.2% low-dose, 63.6% high-dose and 50.0% placebo), GI disorders 
(41.6% low-dose, 52.3% high-dose and 36.4% placebo). More serious adverse events (SAEs) 
occurred in the voclosporin groups (25.8% low-dose, 25.0% high-dose, 15.8% placebo), and 
were consistent with those observed in LN patients. There were 13 deaths (4.9%) during the 
study. There were more deaths in the voclosporin low-dose arm (10) than in either the 
voclosporin high-dose (2) or placebo (1) arms, with the majority (11/13) occurring in Asia. All 
deaths were assessed by the Investigators as unrelated to study treatment.  
In summary, no unexpected safety signals were observed with the use of voclosporin in LN 
subjects; voclosporin was generally well tolerated. The overall safety profile is consistent with 
the expectations for the class of drug, the patient population, and concomitant therapies.  
The AURION study (protocol AUR-VCS-2014-01) is an exploratory open-label Phase 2 study 
assessing the short-term predictors of remission of voclosporin 23.7 mg BID in combination 
with standard of care in patients with active LN. The duration of the study is 48 weeks with 
10 subjects randomized. All subjects received background therapy with MMF and 
corticosteroids. At 24 weeks, 4/7 (57.1%) subjects continued to be in complete remission as 
measured by a UPCR of ≤0.5 mg/mg, eGFR within 20% of baseline, and concomitant steroid 
dose of less than 5 mg/day. Within these 7 AURION patients, there was a 54% mean reduction 
in proteinuria at 24 weeks compared to pre-treatment levels along with consistent 
improvements in complement 3 (C3), C4 and anti-double-stranded DNA. Renal function as 
measured by eGFR remained stable. Voclosporin was well tolerated with no unexpected safety 
signals observed.  
1.2.5 Potential Toxicities 
Voclosporin has been studied in numerous disease states. When examining LN, there were a 
small proportion of voclosporin treated subjects that experienced an early drop of ≥30% in 
eGFR, however that proportion then remains stable over time. None of these treatment-
emergent adverse events (TEAEs) were classed as serious. The majority of TEAEs of 
decreased GFR were classed as mild or moderate, and resulted in permanent discontinuation 
of study drug in 1 (1.1%) placebo subject, 6 (6.7%) voclosporin low-dose subjects and 5 (5.6%) 
voclosporin high-dose subjects. There were more TEAEs of hypertension seen in the 
voclosporin-treated patients compared to placebo however, overall mean systolic and diastolic 
blood pressure (BP) decreased in all groups, without statistically significant differences seen 
between groups. Overall, only 1 (1.1%) subject, in the voclosporin high-dose group, had a 
TEAE of hypertension that resulted in permanent discontinuation of study drug.  
There was evidence of an increased incidence of TEAEs over placebo and with increased dose 
of voclosporin in the System Organ Classes of Infections and Infestations, Gastrointestinal 
Disorders, and Vascular Disorders. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 32 of 114 
 
There were more deaths in the voclosporin low-dose arm (10) than in either the voclosporin 
high-dose (2) or placebo (1) arms, with the majority (11/13) occurring in South-East Asia. All 
deaths were assessed by the Investigator and Data and Safety Monitoring Board (DSMB) as 
unrelated to study treatment. A full description of adverse events can be found in the IB. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 33 of 114 
 
2. RATIONALE 
The rationale for the development of Orelvo and the choice of doses is to introduce a novel 
CNI to the LN patient population, with meaningful efficacy while minimizing toxicities 
common to other CNIs. In clinical studies, a favorable efficacy/safety profile for Orelvo has 
been demonstrated in the prevention of renal transplant rejection. 
As evaluated in nonclinical and clinical studies (healthy volunteers, moderate to severe 
psoriasis, renal transplantation, and uveitis) Orelvo is well tolerated and exhibits AEs that are 
typical of other CNIs yet seen to a lesser extent than that seen historically with other CNIs. 
The aim of the current study is to investigate whether Orelvo, added to the standard of care 
treatment in active LN, is able to reduce disease activity over a treatment period of 52 weeks. 
The background therapy will be MMF at a dose of at least 1 g/day and initial treatment with 
IV methylprednisolone, followed by a reducing course of oral corticosteroids. Subjects with 
active, flaring LN will be eligible to enter the study. They are required to have a diagnosis of 
LN according to established diagnostic criteria (American College of Rheumatology) and 
clinical and biopsy features suggestive of active nephritis. Efficacy will be assessed by the 
ability of the drug combination to reduce the level of proteinuria (as measured by urine 
protein/creatinine ratio (UPCR)) while demonstrating an acceptable safety profile. Normally, 
most subjects will respond to treatment by 6 months, but the optimal short-term predictor of 
long-term renal function is the response to treatment by 12 months (as observed in the 
AURA-LV study). Therefore, the primary endpoint of the Phase 3 study will be complete renal 
response at 52 weeks. 
2.1 
Dose Rationale 
This Phase 3 study is designed to evaluate the treatment benefit of Orelvo 23.7 mg BID versus 
placebo. Orelvo and/or placebo are herein referred to as study treatment. The selection of 
Orelvo dose in this study (see Section 7, Study Treatments) was based on the previous 
experience with this drug in the Phase 2 study (AURA-LV). In AURA-LV, subjects were 
administered voclosporin 23.7 mg BID, 39.5 mg BID, or matching placebo. Low-dose 
voclosporin was significantly superior to placebo in the proportion of subjects achieving 
complete renal response at Week 24 (p=0.045). There was no increase in efficacy with the 
higher dose and no significant differences between the 2 voclosporin groups in achievement 
of renal response.  
Orelvo 23.7 mg BID will be administered as a fixed dose without the use of therapeutic drug 
monitoring. Population PK analyses of voclosporin concentrations from the clinical 
development program (including healthy subjects, subjects with renal impairment, subjects 
with hepatic impairment, renal transplant, and plaque psoriasis) demonstrated that weight did 
not have a significant effect on the PKs of voclosporin. The protocol contains provisions for 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 34 of 114 
 
management of dose based on safety concerns, in particular, BP and renal function. The safety 
data from the use of voclosporin demonstrates that these risks are dose-related, reversible, and 
can be managed by dose reduction and temporary interruption.   

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 35 of 114 
 
3. STUDY OBJECTIVES 
3.1 
Primary Objective 
• To assess the efficacy of Orelvo (voclosporin) compared with placebo in achieving renal 
response after 52 weeks of therapy in subjects with active LN 
3.2 
Secondary Objective 
• To assess the safety and tolerability of Orelvo over 52 weeks compared with placebo in 
subjects with active LN 
3.3 
Endpoints 
3.3.1 Primary Endpoint 
Renal response at Week 52 will be adjudicated by the Clinical Endpoints Committee (CEC) 
based on the following parameters: 
• UPCR of ≤0.5 mg/mg, and 
• eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of >20%, 
and 
• Received no rescue medication for LN (see Section 7.8, Prohibited Therapy and 
Concomitant Treatment), and 
• Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in 
total during Weeks 44 through 52, just prior to the renal response assessment 
Subjects who withdraw from the study prior to the Week 52 assessment will be defined as 
non-responders. 
3.3.2 Secondary Endpoints 
3.3.2.1 Key Secondary Endpoints 
• Time to UPCR of ≤0.5 mg/mg 
• Partial renal response as defined by 50% reduction from baseline in UPCR at Weeks 24 
and 52 
• Time to 50% reduction in UPCR from baseline 
• Renal response at Week 52 (based on definition of primary endpoint) 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 36 of 114 
 
• Duration of UPCR ≤0.5 mg/mg 
• Proportion of subjects experiencing a confirmed >30% decrease from baseline in eGFR 
at each timepoint 
3.3.2.2 Other Secondary Endpoints 
• Change from baseline in UPCR at each time point 
• Change from baseline in serum creatinine, urine protein, and eGFR 
• Change from screening in immunology parameters (complement 3 (C3), C4, and anti- 
double-stranded deoxyribonucleic acid (dsDNA)) at Weeks 24 and 52 
• Renal response with low-dose steroids (defined as renal response in the presence of 
corticosteroids of ≤2.5 mg/day between Weeks 16 to 24 and Weeks 44 to 52) 
• Change from baseline in health-related quality of life (HRQoL) at Weeks 12, 24, and 
52 
• Health Resource Utilization at Weeks 24 and 52 
• Change from baseline in the Safety of Estrogens in Lupus Erythematosus National 
Assessment - Systemic Lupus Erythematosus Disease Activity (SELENA-SLEDAI) 
Index score at Weeks 24 and 52 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 37 of 114 
 
4. INVESTIGATIONAL PLAN 
4.1 
Overall Study Design 
This is a Phase 3, multicenter, randomized, prospective, double-blind, parallel-group, 
placebo-controlled, 2-arm comparison study of Orelvo versus matching placebo. Subjects who 
have provided a signed and dated informed consent will be screened into the study up to 
30 days before randomization. During the screening period, eligibility criteria will be assessed. 
A kidney biopsy may be performed, provided the subject has given consent and provided the 
results can be obtained and reviewed before baseline. Subjects who meet all of the inclusion 
criteria and none of the exclusion criteria will be eligible for randomization into the study. 
Baseline assessments will be performed before the first dose of study treatment is administered 
on Day 1. The baseline assessments of the serum creatinine and urine protein laboratory 
parameters will be established by using the mean of the 2 pre-randomization values. Using an 
interactive web response system (IWRS), eligible subjects will be randomized to receive either 
oral Orelvo 23.7 mg BID or matching placebo for 52 weeks. All subjects should receive 
0.5 g/day IV methylprednisolone on Days 1 and 2 before changing to a reducing course of oral 
corticosteroid therapy on Day 3. (For additional details and exceptions, see Section 7.2.2.2, 
Corticosteroids). Starting at the Baseline Visit, all subjects will also receive background 
therapy with MMF (see Section 7.2.2.3, Mycophenolate Mofetil (Background Therapy). 
All subjects will return for assessment of efficacy and safety at Day 2 and Weeks 2, 4, 8, 12, 
16, 20, 24, 30, 36, 42, 48, and 52. See Schedule of Events, for detailed information regarding 
visits. In addition, subjects not on MMF during screening, will start receiving MMF at the 
Baseline Visit and will return for local complete blood count assessments at Weeks 1 and 3 
after randomization. 
All subjects, completed or withdrawn, will complete the End of Treatment/Early Termination 
assessments (Visit 15) at Week 52 or at the time of early termination. Subjects who do not 
enroll in the continuation study will attend the Safety Follow-up Visit (Visit 16) at Week 56 to 
collect any new AEs and concomitant medications. At the follow-up visit, UPCR and eGFR 
will be assessed as well. For subject withdrawal procedures and criteria, see Section 5.5, 
Withdrawal of Subjects. 
4.2 
Duration of Subject Participation and Study 
The expected duration of subject participation is approximately 60 weeks. The screening 
period is up to 30 days and the treatment duration is 52 weeks, with a further follow-up visit 
4 weeks after last dose (completion or early termination) if not participating in the continuation 
study. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 38 of 114 
 
5. SELECTION, WITHDRAWAL OF SUBJECTS AND PERMANENT 
DISCONTINUATION OF DRUG 
5.1 
Number of Subjects 
It is anticipated that approximately 324 subjects (162 in the Orelvo 23.7 mg BID treatment 
group and 162 subjects in the placebo group) will be randomized in this study.  
5.2 
Inclusion Criteria 
The following inclusion criteria must be met for each subject: 
1. Written informed consent before any study-specific procedures are performed. 
2. Male or female subjects with a minimum age of 18 (or legal age of consent if >18 years) 
to 75 years of age, inclusive, at the time of screening (Visit 1). 
3. Previous diagnosis of SLE according to the American College of Rheumatology criteria 
(1997; see Appendix 5). 
4. Subjects with evidence of active nephritis, defined as follows: 
Kidney biopsy result within 2 years prior to screening indicating Class III, IV-S, IV-G 
(alone or in combination with Class V), or Class V LN (see Appendix 3) with a doubling 
or greater increase of UPCR within the last 6 months to a minimum of ≥1.5 mg/mg for 
Class III/IV or to a minimum of ≥2 mg/mg for Class V at screening. Biopsy results over 
6 months prior to screening must be reviewed with a medical monitor to confirm 
eligibility. 
OR 
Kidney biopsy result within 6 months prior to screening indicating Class III, IV-S, or 
IV-G (alone or in combination with Class V) LN with a UPCR of ≥1.5 mg/mg at 
screening. 
OR 
Kidney biopsy result within 6 months prior to screening indicating Class V LN and a 
UPCR of ≥2 mg/mg at screening.  
A biopsy can be performed during screening, if not available. The above criteria must be 
fulfilled at baseline. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 39 of 114 
 
5. In the opinion of the Investigator, subject requires high-dose corticosteroids and 
immunosuppressive therapy. 
6. Subject is willing to take oral MMF for the duration of the study, either by continuing 
current MMF therapy or by initiating it on or before the Baseline Visit. 
7. Women of childbearing potential must have a negative serum pregnancy test at screening 
and a negative urine pregnancy test at baseline. Two effective forms of contraception must 
be used simultaneously unless abstinence is the chosen method. Subjects must use effective 
contraception during the study (see Section 5.4, Adequate/Effective Contraception). 
5.3 
Exclusion Criteria 
1. Subjects unable or unwilling to give written informed consent and/or to comply with study 
procedures. 
2. eGFR as calculated by the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) 
equation 
of 
≤45 mL/min/1.73 m2 
at 
screening 
confirmed 
before 
randomization. 
3. Currently taking or known need for any of the medications listed in Section 7.8, Prohibited 
Therapy and Concomitant Treatment at screening or during the study. This includes 
prohibited medications prior to screening as specified in Section 7.8.1, Prohibited 
Medications. 
4. Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to 
require dialysis during the study period. 
5. A previous kidney transplant or planned transplant within study treatment period. 
6. Any known hypersensitivity or contraindication to MMF, mycophenolic acid, 
cyclosporine, corticosteroids or any components of these drug products. 
7. Current or medical history of: 
• Congenital or acquired immunodeficiency. 
• In the opinion of the Investigator, clinically significant drug or alcohol abuse within 
2 years prior to screening. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 40 of 114 
 
• Malignancy within 5 years of screening, with the exception of basal and squamous cell 
carcinomas treated by complete excision. Subjects with cervical dysplasia that is 
cervical intraepithelial neoplasia 1, but have been treated with conization or loop 
electrosurgical excision procedure, and have had a normal repeat Papanicolaou test are 
allowed. 
• Lymphoproliferative disease or previous total lymphoid irradiation. 
• Severe viral infection (e.g., cytomegalovirus, hepatitis B virus, hepatitis C virus) within 
3 months of screening; or known HIV infection. Severe viral infection is defined as 
active disease requiring antiviral therapy. 
• Active TB, or known history of TB/evidence of old TB if not taking prophylaxis with 
isoniazid (see Section 9.2.1, Screening Visit Procedures). 
8. Other known clinically significant active medical conditions, such as: 
• Severe cardiovascular disease including congestive heart failure, history of cardiac 
dysrhythmia or congenital long QT syndrome. QT interval duration corrected for heart 
rate using method of Fridericia (QTcF) exceeding 480 msec in the presence of a normal 
QRS interval (<110 msec) at time of screening will result in exclusion. 
• Liver dysfunction (aspartate aminotransferase, alanine aminotransferase, or bilirubin 
≥2.5 times the upper limit of normal) at screening and, if abnormal at screening, then 
confirmed that the levels have returned to <2.5 times upper limit of normal before 
randomization. 
• Chronic obstructive pulmonary disease or asthma requiring oral steroids. 
• Bone marrow insufficiency unrelated to active SLE (according to Investigator 
judgment) with white blood cell count <2,500/mm3; absolute neutrophil count (ANC) 
<1.3 × 103/μL; thrombocytopenia (platelet count <50,000/mm3). 
• Active bleeding disorders. 
• Current infection requiring IV antibiotics. 
9. Any overlapping autoimmune condition for which the condition or the treatment of the 
condition may affect the study assessments or outcomes (e.g., scleroderma with significant 
pulmonary hypertension; any condition for which additional immunosuppression is 
indicated). Overlapping conditions for which the condition or treatment is not expected to 
affect assessments or outcomes (e.g., Sjögren’s syndrome) are not excluded. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 41 of 114 
 
10. No vaccines using live organisms, virus or bacterial, are allowed during screening and 
while taking the study treatment. 
11. Other major physical or psychiatric illness or major traumatic injury within 6 months prior 
to screening that may affect study conduct or interfere with study assessments or outcome. 
12. Any other medical condition which, in the Investigator’s judgment, may be associated with 
increased risk to the subject or may interfere with study assessments or outcomes. 
13. Subjects who are pregnant, breast feeding or, if of childbearing potential, not using 
adequate contraceptive precautions. 
14. Participation in another clinical study within 4 weeks prior to screening and/or receipt of 
investigational drugs within 4 weeks or 5 half-lives of the drug (whichever is longer) prior 
to screening. 
15. Subjects randomized and treated in a previous voclosporin clinical study. 
5.4 
Adequate/Effective Contraception 
Women of childbearing potential must have a negative serum pregnancy test at screening and 
a negative urine pregnancy test at baseline. Two effective forms of contraception must be used 
simultaneously unless abstinence is the chosen method. Effective contraception must be used 
before beginning study treatment, during study dosing, and for 6 weeks following 
discontinuation of study treatment or MMF dosing, even when there has been a history of 
infertility, unless due to surgical sterilization. Women not of childbearing potential are defined 
as women without menses for at least 12 consecutive months or surgically sterilized. 
Sexually active men, both reproductively competent and vasectomized, are required to use 
condoms during treatment and for at least 90 days after cessation of study treatment or MMF. 
In addition, female partners of male subjects are recommended to use an effective 
contraception during their partner’s treatment and for at least 90 days after the last dose of 
study treatment or MMF. Male subjects are to refrain from making sperm donations during 
treatment and for at least 90 days after cessation of study treatment or MMF. 
An effective and medically acceptable method of birth control means the chance of pregnancy, 
when using that type of birth control, is less than 1% per year if used correctly. These birth 
control methods (i.e., reliable forms of contraception) include birth control pills (combined 
oral contraceptives), hormone implants, hormone shots, and some intrauterine contraceptive 
devices. The use of MMF in this study can also reduce the effectiveness of the oral 
contraceptive pill.  

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 42 of 114 
 
Barrier methods (e.g., condoms, diaphragm, or cervical cap/sponge) when used alone are not 
highly considered effective. 
Although abstinence, when adhered to, is an effective method of birth control, other additional 
effective contraception methods should be used where there is any doubt. The method of 
contraception needs to be discussed with the Investigator throughout the study period in order 
to confirm the method used is considered effective. 
5.5 
Withdrawal of Subjects 
Subjects may voluntarily withdraw from study participation at any time for any reason. 
Alternatively, subjects may be withdrawn at the Investigator’s discretion if it is in the subject’s 
best interest. 
Every effort should be made for subjects who withdraw from the study, either voluntarily or at 
the Investigator’s discretion, to undergo end of study assessments (Visit 15), if possible. If 
possible, the subject should also be advised to come for the Safety Follow-up Visit 4 weeks 
after last dose. If a subject refuses end of study procedures, the reason for refusal should be 
fully documented in the subject’s source document and recorded in the study specific electronic 
case report form (eCRF). It is the subject’s right to withdraw from the study without providing 
a reason. In this case, the source documents and the eCRF should document the reason for 
discontinuation as “withdrawal of consent.” Withdrawn subjects will not be replaced. 
5.6 
Discontinuation of Study Treatment 
If any subject is discontinued from study treatment, the reason for discontinuation will be 
documented in the eCRF. If the reason for discontinuing study treatment is an AE or an 
abnormal laboratory test result, the specific event or test will be recorded in the eCRF. Except 
for cases involving pregnancy, subjects who are discontinued from study treatment should 
undergo all study assessments up to and including (Week 52 or Early Termination Visit – 
Visit 15), if possible. The subject should also be advised to come for the Safety Follow-up 
Visit 4 weeks after last dose. Guidance on when study treatment must be discontinued is in 
Section 7.6, Orelvo/Placebo Dose Modification.  
5.6.1 Discontinuation from Study Treatment Due to Early Non-response to 
Therapy 
Subjects will be discontinued from study treatment if their early disease response is 
suboptimal. The Investigator must contact the Medical Monitor to discuss further continuation 
in the study if the subject meets 1 of the 2 following criteria: 
• After 12 weeks of treatment, the subject shows a >30% decrease from baseline value 
in CKD-EPI eGFR in 2 successive measurements separated by at least 4 weeks 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 43 of 114 
 
or 
• After 8 weeks of treatment, the subject shows a confirmed reduction in UPCR of ≤25% 
assessed by 2 consecutive measurements at least 2 weeks apart. 
If the subjects require treatment with IV methylprednisolone or any rescue medication other 
than that permitted in the protocol (see Section 7.2.2.2, Corticosteroids), they should be 
permanently discontinued from the study treatment and will be considered a treatment failure. 
Subjects who are permanently discontinued from study treatment will be treated as deemed 
appropriate by the Investigator. 
5.6.2 Discontinuation of Study Treatment Due to an Adverse Event 
Subjects may be permanently discontinued from study treatment because of the appearance of 
an unacceptable AE. It is vital to obtain follow-up data on any subject withdrawn because of 
an AE. In any case, every effort must be made to evaluate protocol-specified safety follow-up 
procedures (see Section 10.3, Reporting Procedure for AEs, SAEs, and Pregnancy). If a subject 
is withdrawn due to an AE, the event should be followed by the Investigator through contact 
with the subject until resolution or stabilization has occurred. All AEs should be followed until 
resolution, stabilization or the subject is lost to follow-up and cannot be contacted. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 44 of 114 
 
6. RANDOMIZATION, BLINDING AND UNBLINDING PROCEDURES 
6.1 
Randomization 
All subjects enrolled must be identifiable throughout the study. The Investigator will maintain 
a list of subject numbers and subject names to enable records to be found at a later date. 
Subjects will be allocated a subject number at the screening visit and registered with an 
interactive central randomization system. Subjects meeting the required eligibility criteria will 
be randomized to treatment at Visit 2 (baseline). The randomization will be stratified by biopsy 
class (Class V only versus Others) and by prior MMF use at time of screening. The subjects 
will be randomized in a ratio of 1:1 to receive either Orelvo 23.7 mg BID or matching placebo. 
To help ensure balance, a centralized randomization will be utilized where region will be 
employed as a blocked factor. 
Details on randomization procedures will be provided in a separate manual. 
6.2 
Blinding 
In order to preserve the double-blind design, subjects randomized to the placebo group will be 
matched to the active dosage groups. Dosing schedule in the placebo group will be the same 
as that of the active treatment group. To this end, the double-blind nature of this study preserves 
the blind with respect to active study treatment and placebo. 
All study personnel and subjects will be blinded to the study treatment administered during the 
study. Orelvo and placebo will be identical in taste, smell, and appearance. The randomization 
code key will not be available to the Study Monitors, project statisticians or the project team 
at Aurinia Pharmaceuticals Inc. (Aurinia) or its representatives. The site staff, monitors, and 
study subjects will remain blinded until the end of the study. In case of emergency, the 
unblinding process below should be followed. 
6.3 
Unblinding 
In the rare event that an AE or pregnancy occurs for which knowledge of the identity of the 
study treatment administered is necessary to manage the subject’s condition, the IWRS code 
for that subject may be broken and the test substance identified. Procedures for unblinding will 
be provided in a separate manual. 
Should emergency unblinding be required, the Investigator should call the 
 
 Medical Monitor before unblinding wherever possible; however, the 
Investigator is responsible for the medical care of the individual study subject, and does not 
require the agreement of the Medical Monitor before unblinding. The reason for unblinding 
must be documented. The information on study treatment should only be used for decision 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 45 of 114 
 
making in the subject’s further treatment. Details on unblinded treatment assignments should 
not be shared with the Study Monitor and project team. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 46 of 114 
 
7. STUDY TREATMENTS 
7.1 
Dosage Forms/Formulation 
All study treatment to be used in this study will be manufactured in accordance with current 
Good Manufacturing Practice (GMP). Study treatment will be supplied by Aurinia. 
7.1.1 Orelvo– Study Treatment 
Company Code: 
 
Chemical Name: 
 
Empirical Formula: 
 
Generic Name: 
Voclosporin 
Dosage Form: 
Softgel capsules 
Strength: 
7.9 mg of voclosporin per softgel capsule 
Manufacturer: 
 
7.1.2 Placebo Control 
Placebo softgel capsules, identical to 7.9 mg Orelvo softgel capsules, will be provided. 
7.1.3 Background Therapy 
7.1.3.1 Mycophenolate Mofetil 
Oral MMF in the form of 500 mg tablets will be centrally supplied by Aurinia. Aurinia will 
reimburse the cost of the MMF tablets if not centrally provided by Aurinia to the sites.  
7.1.3.2 Corticosteroids 
Intravenous and oral corticosteroids will be prescribed at the investigational sites and costs will 
be reimbursed by Aurinia. 
7.2 
Drug Dosage and Administration 
7.2.1 Treatment Arms 
All subjects will receive either 3 capsules of Orelvo (23.7 mg BID) or matching placebo BID. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 47 of 114 
 
Orelvo – 23.7 mg (3 capsules) BID 
Orelvo 23.7 mg BID; 3 capsules administered BID in combination with MMF and oral 
corticosteroids from randomization onwards. 
Placebo – 3 capsules BID 
Placebo; 3 capsules administered BID in combination with MMF and oral corticosteroids from 
randomization onwards. 
7.2.2 Dosing Guidelines 
7.2.2.1 Orelvo/Placebo – Study Treatment 
Study treatment will be taken BID with water on an empty stomach as close to a 12 hour 
schedule as possible, and with a minimum of 8 hours between doses. If the subject misses a 
dose of study treatment by less than 4 hours from the anticipated dosing time, the missed dose 
will be taken immediately. The next dose will be taken at the originally scheduled time. If a 
missed dose of study treatment is greater than 4 hours from the expected dosing time, the 
subject will skip the dose and take the next dose at the originally scheduled time. The variation 
in dosing will be recorded in the eCRFs. The dose/doses of study treatment may be held at the 
discretion of the Investigator. Subjects must avoid consumption of grapefruit or grapefruit-
containing juice (e.g., pomelo) for the duration of their participation in the study. 
Possible dose adjustments: If GI or other disturbances occur with study treatment, then study 
treatment dosing may be reduced or interrupted, and/or appropriate treatment may be initiated 
(e.g., addition of a proton pump inhibitor (see Appendix 5) and Section 7.6, Orelvo/Placebo 
Dose Modification). 
All unused study treatments (and any empty containers) dispensed to the subject will be 
returned at each study visit for capsule counts to check compliance. The Investigator will count 
the returned study treatment and this information will be used to assess subject compliance. 
This study treatment count must be documented in the eCRF and source documentation. 
7.2.2.2 Corticosteroids 
All subjects who weigh ≥45 kg should receive 0.5 g IV methylprednisolone on both Day 1 and 
Day 2 (a total of 1 g), before oral corticosteroid therapy is started on Day 3. All subjects who 
weigh <45 kg should receive 0.25 g IV methylprednisolone on both Day 1 and Day 2 (a total 
of 0.5 g). When subjects are receiving IV methylprednisolone, they should not receive oral 
corticosteroids on the same day. 
If it is considered to be in the subject’s best interest, IV methylprednisolone treatment may be 
started during the screening period, but no more than 1 g in total may be administered for the 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 48 of 114 
 
screening period and Day 1 and/or Day 2 combined (0.5 g in subjects who weigh <45 kg). 
Subjects receiving IV methylprednisolone in the 3 months prior to screening must be discussed 
with the Medical Monitor prior to initiating further IV methylprednisolone. Also, IV 
corticosteroid therapy to be administered during screening must be discussed with the Medical 
Monitor in advance. If IV corticosteroid therapy is administered by the site during screening, 
the dose administered on Day 1 and/or Day 2 will be 1 g minus the dose administered during 
screening. The maximum daily dose of methylprednisolone administered on Day 1 and/or 
Day 2 is 0.5 g. See below for examples: 
• Example 1: If a 0.6 g dose of IV methylprednisolone is administered during screening, 
then (1 – 0.6) = 0.4 g IV methylprednisolone will be administered on Day 1, followed 
by the oral steroid dosing schedule in Table 1, beginning on Day 2 or 3. 
• Example 2: If the dose administered during screening is 0.3 g, then the total residual 
dose required is (1 – 0.3) = 0.7 g. Because 0.7 g is greater than the maximum daily dose 
allowed, 0.35 g will be administered on Day 1 and 0.35 g on Day 2, followed by the 
oral steroid dosing schedule in Table 1, beginning on Day 3. If IV methylprednisolone 
therapy is administered in the 2 weeks prior to the start of screening then the subject is 
excluded from the study (see Section 7.8.1, Prohibited Medications), unless approved 
by the Medical Monitor. 
• Example 3: In a 40 kg subject, if a 0.3 g dose of IV methylprednisolone is administered 
during screening then (0.5 – 0.3) = 0.2 g IV methylprednisolone will be administered 
on Day 1, followed by the oral steroid dosing schedule in Table 1, beginning on Day 2 
or 3. 
If at screening the Investigator determines a subject requires IV corticosteroid therapy, every 
effort should be made to collect both morning urine specimens (for UPCR determination) 
before initiation of the IV steroids. If this cannot be done, the Medical Monitor should be 
contacted in advance of the therapy (see Section 9.2.1, Screening Visit Procedures). 
In the case of the full 1 g IV methylprednisolone being administered prior to randomization 
(or 0.5 g in a subject <45 kg), it is acceptable for oral prednisone as per dosing schedule to be 
administered on Day 1. 
The starting dose of oral prednisone will be 20 mg/day for subjects <45 kg and 25 mg/day for 
subjects ≥45 kg. The dose will be reduced according to the tapering schedule below, see 
Table 1. Refer to Appendix 4 for a conversion table of various formulations of steroids. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 49 of 114 
 
Table 1 
Dosing Schedule for IV Methylprednisolone and Daily Oral 
Prednisone (mg) 
 
Subjects 
<45 kg 
Subjects 
≥45 kg 
In Case of Prior IV Steroids 
During Screening (Pre-randomization) 
Weeks 1-2(1) 
 
 
 
Days 1-2(2) 
0.25 g (IV) 
0.5 g (IV) 
1 g minus prior IV steroids mg or (0.5 g minus 
prior IV steroids mg for subjects who weigh 
<45 kg)(3) 
Days 3-13 
20 mg (oral) 
25 mg (oral) 
 
Week 2 (Day 14) 
15 mg (oral) 
20 mg (oral) 
 
Week 4 (Day 28) 
10 mg (oral) 
15 mg (oral) 
 
Week 6 (Day 42)(4) 
10 mg (oral) 
10 mg (oral) 
 
Week 8 (Day 56) 
5 mg (oral) 
5 mg (oral) 
 
Week 12 (Day 84) 
5 mg (oral) 
5 mg (oral) 
 
Week 16 (Day 112) 
2.5 mg (oral) 
2.5 mg (oral) 
 
1 Day 0-13: Oral steroids dosed according to subject weight and then tapered beginning at Day 14. 
2 Oral corticosteroids may be commenced on Days 1 or 2 if corticosteroids are administered during screening. 
3 It is recognized that dosing with IV methylprednisolone as described in Section 7 2 2 2, Corticosteroids may not be in the subject’s best 
interest if they have already received therapy within the 3 months prior to screening. In this case, the Investigator may be permitted to 
omit the administration of further IV methylprednisolone but only after discussion with the Medical Monitor. 
4 Week 6 is not a scheduled study visit, a phone call can be performed to decide further tapering for subjects. 
 
Notes: Oral prednisone taper should be done within ±3 days of specified timeframe. When clinically indicated, subjects are allowed to be 
completely titrated off of oral corticosteroids. 
Abbreviation: IV = Intravenous. 
 
Note that at each visit or during interim phone calls, the corticosteroid dose to be achieved is 
shown. The timing of the titration to that dose is at the discretion of the Investigator. For 
example, the Week 6 administration of steroids in a 43 kg subject should be 10 mg daily. The 
Investigator may reduce it at Week 7 to 7.5 mg until 5 mg is prescribed at Week 8. 
When clinically indicated, subjects are allowed to be completely titrated off of oral 
corticosteroids. 
Subjects with a lack of response are allowed one 4-week interval without dose reduction or 
1 dose escalation to the previous dose for 2 weeks at any time during the study. Lack of 
response is defined as no or minimal change in UPCR per Investigator judgment over 3 visits 
or deterioration in UPCR not meeting the criteria for withdrawal. All deviations from the 
prescribed dosing schedule in Table 1 above must be discussed with the Medical Monitor and 
documented in the source notes and eCRF. 
7.2.2.3 Mycophenolate Mofetil (Background Therapy) 
Subjects receiving MMF prior to randomization will continue without interruption.  

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 50 of 114 
 
• Subjects must be counselled on the risk of pregnancy while taking MMF and the need 
for adequate contraceptive precautions (see Section 5.4, Adequate/Effective 
Contraception). 
• Subjects on AZA or mycophenolate sodium at screening must switch to MMF at 
baseline (Day 1). 
• For subjects who are not already taking prescribed MMF prior to randomization, the 
dosing of MMF will start at 500 mg BID for a total daily dose of 1 g/day for the first 
week, increasing to 1 g BID for a total daily dose of 2 g/day for the second and 
subsequent weeks (i.e., beginning on Day 8).  
• Complete blood count must be performed locally at Weeks 1 and 3 in subjects not 
already taking MMF at screening (unscheduled visit or not). 
All subjects will take MMF BID (morning and evening), before meals (i.e., on an empty 
stomach), with a glass of water. If a dose is missed, the subject should take the next correct 
dose rather than “doubling up” at the next dosing time point. A stable dose of MMF will be 
maintained throughout the study. Dose changes or interruptions are permitted for clearly 
documented safety reasons only. 
• Approval by the Medical Monitor is required for subjects taking a dose other than 
2 g/day MMF from randomization onwards (e.g., total daily dose of 1 or 3 g/day). 
• If GI disturbance or other side-effects occur with MMF, the 1 g BID dosing may be 
changed to 500 mg four times daily. 
• If a subject has an ANC <1,500/mm3 at any study visit, the dose of MMF should be 
decreased or interrupted. If a subject has an ANC <1,000/mm3 at any visit, the dose 
should be discontinued and only recommenced when the ANC reaches 1,500/mm3. If 
the subject has a dose interruption of MMF of >14 days, then permanent 
discontinuation of MMF, therefore the study, should be considered after discussion 
with the Medical Monitor. 
• If deemed necessary by the Investigator on account of leukopenia or other adverse 
effect, or if the subject weighs 50 kg or less, the dose of MMF may be decreased to a 
minimum of 500 mg BID. 
7.3 
Package and Labeling 
All study treatments provided by Aurinia will be packaged and labeled for Aurinia by 
appropriately qualified vendors according to all applicable local and country regulatory 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 51 of 114 
 
requirements. All packaging and labeling operations will be performed according to GMP and 
Good Clinical Practice (GCP). 
Study-treatment wallets provided to sites and to subjects will be labeled in the appropriate local 
language, according to local regulatory requirements. 
Wallet label information will be appropriately documented in the Drug Accountability Form 
after the container has been dispensed to the subject. 
7.4 
Study Treatment Allocation 
For purposes of randomization, each eligible subject will be assigned to 1 of the 2 treatment 
groups in a 1:1 ratio using IWRS. The randomization will be central-based and stratified by 
biopsy class (Class V only versus Others) and by prior MMF use at time of the Screening Visit. 
Randomization will additionally be blocked by region. 
7.5 
Site Supply, Storage, Accountability 
7.5.1 Site Supply 
Once a site has been approved for study initiation, the site will be supplied with an initial stock 
of study treatment. The need for study treatment resupply will be assessed on a regular basis 
taking into account the number of subjects enrolled at the site. 
7.5.2 Storage 
Orelvo softgel capsules and matching placebo capsules will be supplied in cartons containing 
168 capsules in 4 wallets of 42 capsules each. 
The Investigator must ensure the availability of proper storage conditions. All study treatment 
supplies provided for this study will be stored in a secure area with restricted access at the 
study site. The capsules must be stored at a controlled room temperature between 15 and 30°C 
(59-86°F). The Investigator must document and inform the Site Monitor about temperature 
deviations outside the acceptable range. Subjects will be instructed to store the study treatment 
at room temperature between 15 and 30°C (59-86°F). 
Each site should have a thermometer that records minimum and maximum temperatures daily. 
Maintenance of a temperature log is mandatory. The log should be updated by site personnel 
during normal working hours. This log must be available for review by the Site Monitor during 
on-site monitoring visits. 
7.5.3 Accountability 
The Investigator at each site is responsible for study treatment supplies. The Investigator will 
ensure that adequate records of the receipt, dispensing, and return of the study treatment are 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 52 of 114 
 
kept and that the study treatment is used only for subjects enrolled in the study. All data 
regarding the study treatment must be recorded on the relevant forms provided. 
Each study site will maintain a drug inventory/dispensing record for all drugs dispensed and 
returned. At the end of the study, 1 copy of the drug inventory/dispensing record should be 
sent to Aurinia for the central study file. The original will be kept in the site files. 
After completion of the study, or if it is prematurely terminated, all unused materials will be 
returned to Aurinia. The decision to destroy study treatment at a site must be made by Aurinia. 
If the study treatment is destroyed at a site, the Investigator must receive Aurinia approval of 
the process and forward the certificate of destruction to Aurinia. 
Records of IV methylprednisolone, oral corticosteroids, and MMF must be maintained 
(prescribed dose, dose adjustments and reasons) in the source notes and must be transcribed 
into the eCRF. 
7.6 
Orelvo/Placebo Dose Modification 
Dose modifications for background therapy (MMF and corticosteroids) are detailed in 
Section 7.2, Drug Dosage and Administration. 
7.6.1 Deterioration in Renal Function 
Serum creatinine and eGFR utilizing the CKD-EPI formula will be used for the assessment of 
renal function at every visit (Visits 1-15 and unscheduled visit(s)). Subjects will have a 
minimum of 2 eGFR measurements conducted prior to dosing at Visit 2. The lowest of the 
pre-dose eGFR assessments will be used as the marker of baseline renal function. 
It is recognized that eGFR may be unreliable at higher values (>100 mL/min/1.73 m2). Lupus 
nephritis subjects with nephrotic range proteinuria frequently have wide fluctuations in serum 
creatinine (and therefore eGFR) which are not representative of true renal dysfunction. Chronic 
kidney disease is defined as eGFR <60 mL/min/1.73 m2 for ≥3 months [20], with or without 
kidney damage.  
7.6.1.1 Decrease in eGFR >30% and eGFR <60 mL/min/1.73 m2 
During the treatment period, any subject experiencing a >30% decrease in eGFR from baseline 
to <60 mL/min/1.73 m2, will have study treatment interrupted until a repeat test can be 
performed (unscheduled visit to be completed). If the decrease is confirmed and not due to 
potential contributing factors (e.g., high baseline eGFR, the addition or modification of 
non-steroidal anti-inflammatory drugs (NSAIDs), angiotensin converting enzyme (ACE) 
inhibitors, angiotensin II receptor blockers (ARBs), a concurrent state of dehydration, 
overdosing with study treatment, lupus renal flare, etc.), the case should be discussed with the 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 53 of 114 
 
Medical Monitor, the study treatment should be withheld, and eGFR retested within 48 hours. 
If the eGFR decrease is not confirmed, the study treatment can be restarted at 2 capsules BID 
and increased as tolerated with discussion with the Medical Monitor. 
7.6.1.2 Decrease in eGFR ≤30% and eGFR <60 mL/min/1.73 m2 
During the treatment period, any subject having a ≤30% reduction in eGFR to 
<60 mL/min/1.73 m2, should have the influence of potential contributing factors (as described 
in Section 7.6.1.1, Decrease in eGFR >30% and eGFR <60 mL/min/1.73 m2) ruled out and 
appropriate corrective action taken. Any subject having a >20-≤30% reduction compared to 
baseline in eGFR to <60 mL/min/1.73 m2 will have a confirmation measurement done within 
approximately 2 weeks (at a planned study visit, if any, or an unscheduled visit is to be 
completed). The subjects will be managed in the most medically appropriate manner in 
consultation with the Medical Monitor. The management of the decrease in eGFR may include 
reduction of dose or temporary interruption. 
7.6.1.3 Recovery of eGFR 
Subjects experiencing a decrease in eGFR with resultant decrease in dose should be reassessed 
for recovery of renal function. If the repeated eGFR is >80% of baseline, the dose should be 
increased by 1 capsule BID and eGFR assessed within 2 weeks. 
7.7 
Procedures for Overdose 
Based on clinical experience with Orelvo, symptomatic treatment of AEs or overdoses is 
indicated. Treatment for renal dysfunction, hypertension, and infection may include dose 
reduction or dose discontinuation. Magnesium supplementation may be required for 
hypomagnesemia. Treatment for GI complaints and biochemical/hematological abnormalities, 
and all other expected AEs, should be based on symptoms, with care taken to rule out other 
causes. 
7.8 
Prohibited Therapy and Concomitant Treatment 
Any concomitant treatment given for any reason during the course of the study must be 
recorded in the eCRF and in the subject’s source documents, including dosage, start and stop 
dates, and reason for use. 
Any class of medications not mentioned below and with the potential to interfere with 
evaluation of the study treatment must be discussed and documented with the Medical Monitor. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 54 of 114 
 
7.8.1 Prohibited Medications 
The following medications cannot be taking during the study: 
• IV corticosteroids within 2 weeks prior to screening (Visit 1) unless approved by the 
Medical Monitor 
• Enteric-coated oral corticosteroids during the study are not allowed. No other use of 
non-enteric coated oral corticosteroids, other than administration required as per 
protocol, is allowed 
• IV immunoglobulin treatment within 2 weeks prior to screening (Visit 1) 
• Cyclophosphamide within 4 weeks prior to screening (Visit 1) 
• Cholestyramine or other drugs that may interfere with enterohepatic recirculation of 
MMF within 4 weeks prior to screening (Visit 1) 
• Initiation of new treatment or change in dosage of ARBs and/or ACE inhibitors within 
4 weeks prior to randomization (Visit 2) 
• CNIs (e.g., cyclosporine and tacrolimus) within 1 month of screening (Visit 1) 
• Immunosuppression biologic agents (e.g., abatacept, belimumab, infliximab, 
adalimumab, etanercept, or rituximab) within 3 months prior to screening (Visit 1) 
• Vaccines using live organisms, viral or bacterial 
• MMF dose other than 2 g/day without prior discussion with the Medical Monitor 
• Concomitant therapy with other immunosuppressants after randomization, other than 
MMF administered per protocol 
• Subjects are allowed to be on AZA or mycophenolate sodium during screening but 
must switch to MMF at randomization 
• Current or planned use of ketoconazole or rifampin 
• Concomitant use of other CYP3A4/5 inhibitors and inducers should be discussed with 
the Medical Monitor 
Appendix 8 contains a summary of additional treatment and food restrictions. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 55 of 114 
 
7.8.2 Allowed Concomitant Medications 
These medications are permitted during the study: 
• Topical steroids (e.g., nose, scalp, skin, inhaled) 
• Antimalarials should be prescribed when clinically indicated 
• Herbal supplements can be used with caution and depending on active ingredients 
Treatments which may be used as medically indicated, according to the judgment of the 
Investigator can be found in Appendix 7. Treatments not included in this list may be acceptable 
in the study; such treatments should be verified with the Medical Monitor prior to use. A 
summary of treatment and food restrictions can be found in Appendix 8. 
7.9 
Increased Blood Pressure 
For all subjects, the target systolic pressure is ≤130 mmHg and the target diastolic pressure is 
≤80 mmHg. Investigators should use all means possible permitted in the protocol to maintain 
the BP within these limits. If no further adjustment of antihypertensive therapy is possible, the 
subject should be discussed with the Medical Monitor. 
If on any study day, systolic BP is >165 mmHg or diastolic BP is >105 mmHg and is associated 
with symptoms of hypertension (i.e., persistent headache, altered mental status, shortness of 
breath, chest pain consistent with angina pectoris, symptoms of heart failure, evidence of renal 
insufficiency of new onset, evidence of hypertensive retinal injury [hemorrhages, 
papilledema]), study treatment should be held, the Medical Monitor contacted, and the subject 
treated as per Investigator local practices and best judgment. The subject will continue with all 
study visits per the Schedule of Events. Study treatment must not be reintroduced without prior 
discussion with the Medical Monitor. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 56 of 114 
 
8. RISKS/PRECAUTIONS 
No evidence available at the time of the completion of this study protocol indicated that special 
warnings or precautions are required, other than those noted in the IB. 
If additional special warnings or precautions become apparent before study completion, 
Aurinia will notify the Investigator at each site. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 57 of 114 
 
9. STUDY PROCEDURES 
9.1 
Description of Study Assessments 
9.1.1 Laboratory Assessments 
Analysis of all samples for hematology, chemistry, hepatic function, lipid profiles, and 
urinalysis will be performed at a central laboratory using standard validated methods (see the 
laboratory manual). All study data analyses involving laboratory values will be based on results 
from the central laboratory. 
The UPCR will be calculated both from the first morning void and from standard urinalysis 
results. If the first morning void is for some reason not available, then standard urinalysis from 
a 24-hour urine collection may be substituted as an exception but only after agreement is 
reached with the Medical Monitor. 
Blood and urine samples for the following efficacy and safety assessments (See Table 2) will 
be drawn in accordance with the Schedule of Events. 
Table 2 
Review of Laboratory Assessments 
Test Type 
Test Parameters 
Collection at Visits 
Hematology 
Complete blood count (CBC) 
 Hematocrit 
 Hemoglobin 
 Mean corpuscular hemoglobin (MCH) 
 Mean corpuscular hemoglobin concentration 
(MCHC) 
 Mean corpuscular volume (MCV) 
 Platelet count 
 Red blood cells (RBC) 
 Red blood cell morphology 
 White blood cells (WBC) 
Differential (absolute and %) 
 Bands 
 Basophils 
 Eosinophils 
 Lymphocytes 
 Monocytes 
 Neutrophils 
Erythrocyte sedimentation rate 
All except Day 2 
 
 
 
 
 
 
 
 
 
 
All except Day 2 
 
 
 
 
 
 
Day 1, Week 24, and Week 52 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 58 of 114 
 
Table 2 
Review of Laboratory Assessments (Cont’d) 
Test Type 
Test Parameters 
Collection at Visits 
Coagulation 
Coagulation 
 Activated partial thromboplastin time (aPTT) 
 Prothrombin time (PT) 
 Partial thromboplastin time (PTT) 
Screening 
Blood Chemistry 
Alanine aminotransferase (ALT) 
Albumin 
Alkaline phosphatase (ALP) 
Aspartate aminotransferase (AST) 
Bicarbonate 
Bilirubin (direct and total) 
Blood urea nitrogen (BUN) 
Calcium 
Chloride 
Cholesterol (total, HDL, and LDL) 
Creatine kinase 
Creatinine 
Gamma-glutamyl transferase (GGT) 
Glucose 
Glycosolated hemoglobin (HbA1c) 
Lactic dehydrogenase (LDH) 
Magnesium 
Phosphorous, inorganic 
Potassium 
Protein, total 
Sodium 
Triglycerides 
c-Reactive Protein 
All except Day 2 
 
 
 
 
 
 
 
 
Day 1, Week 24, and Week 52 
Day 1, Week 24,and Week 52 
 
 
 
Day 1, Week 24, and Week 52 
 
 
Day 1, Week 24, and Week 52 
 
 
 
 
Screening, Week 24, and 
Week 52 
Urinalysis 
Complete urinalysis (to include urine protein, 
creatinine, blood, urine microscopy). First 
morning void will be performed to analyze 
urine protein/creatinine ratio. A 24-hour UPCR 
may be substituted for FMV at entry (or 
endpoint) if required. 
All except Day 2 
Pregnancy Test 
A serum pregnancy test will be performed for 
females of childbearing potential. Urine 
pregnancy tests will be done using a dipstick. 
Screening and Weeks 24 and 52 
(Serum) 
All other applicable visits (Urine) 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 59 of 114 
 
Table 2 
Review of Laboratory Assessments (Cont’d) 
Test Type 
Test Parameters 
Collection at Visits 
Lupus Markers 
Anti-double-stranded DNA (anti-dsDNA) 
antibodies 
Anti-nuclear antibodies (ANA) 
Serum 
 Complement 3 
 Complement 4 
Antiphospholipid antibodies 
Anticardiolipin antibodies 
Lupus anticoagulant test 
Screening, Week 24, and 
Week 52 
 
 
 
 
 
 
 
Serology 
Cytomegalovirus 
Hepatitis A, B, and C 
Hepatitis B surface antigen (HBsAg) 
Screening 
 
Special Tests 
Estimated glomerular filtration rate (eGFR) 
All except Day 2 
Notes: FMV = first morning void; HDL = High-density lipoprotein; LDL = Low-density lipoprotein; UPCR = urine protein creatinine 
ratio. 
Baseline renal function will be the minimum value of any and all eGFR values taken during the screening period and at baseline 
prior to administration of drug (a minimum of the screen and baseline (pre-dose) values. The central lab will need to report a 
baseline value for the analysis. 
 
The total amount of blood that will be collected during the study from an individual subject is 
approximately 300 mL over 56 weeks. 
For details on whether laboratory abnormalities should be reported as AEs and on the 
follow-up required in such cases, see Section 10.2.5, Clinical Laboratory Evaluations. 
9.1.1.1 
Evaluation of Biomarkers 
Samples for biomarker assessments will be obtained in blood / urine and stored (frozen) for 
future analysis for subjects who consent to have their leftover samples retained. 
9.1.2 Physical Examinations 
Physical examinations will be performed in accordance with the Schedule of Events. 
The physical examination will include a review of SLE-related manifestations which will also 
be recorded. A complete physical examination will be conducted at screening and an 
abbreviated physical will be performed at all other visits as per the Schedule of Events. The 
abbreviated examination will consist of checking the normality or abnormality of the following 
body systems: general appearance, cardiovascular system, and pulmonary system. Any 
abnormalities will be recorded in the eCRF and reported as an AE. Because the investigational 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 60 of 114 
 
medication is an immunosuppressant, physical examination will include clinical examination 
for tumors. 
Subject weight will also be recorded at each physical examination; however, height will only 
be recorded at the screening (Visit 1). 
9.1.3 Vital Signs 
The following vital signs will be measured in accordance with the Schedule of Events: 
• Resting BP (systolic and diastolic) 
• Resting HR 
• Body temperature (°C or °F) 
To avoid variability, the same method of obtaining body temperature should be used 
throughout the study. 
9.1.3.1 Blood Pressure Management 
Blood pressure and HR will be measured with the subject in a sitting position after 5 minutes 
of rest. The procedure for standardized measurement of BP is detailed in Appendix 2. 
If the BP measure is confirmed to be >130/80 mmHg (i.e., by the mean of the second and third 
repeats of 3 readings), the subject’s BP will be managed per local practice. If the BP remains 
uncontrolled with the maximal doses of first and second-line antihypertensive therapies 
referenced in Appendix 1, then the Investigator should contact the Medical Monitor to consider 
dose adjustment of the study treatment. See Section 7.9, Increased Blood Pressure for 
management of increased BP. 
9.1.4 Standard 12-lead Electrocardiogram 
The electrocardiogram (ECG) will be a standard 12-lead tracing performed at the 
investigational site, assessed by a qualified physician at the investigational site, and retained 
as a source document. Any abnormalities will be recorded in the eCRF. Electrocardiograms 
will be recorded after the subject has been in a resting, supine position for at least 5 minutes. 
Abnormal ECG tracings can be reviewed by the Medical Monitor. Significant abnormalities, 
including findings that may prompt discontinuation of study treatment, must be discussed with 
the Medical Monitor. 
Electrocardiograms will be measured at screening, Week 12, Week 24, and Week 52. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 61 of 114 
 
9.1.4.1 Procedures to Manage a Treatment-Emergent Increase in QTc 
In the event that a subject has a QTcF value exceeding 500 msec, or an increase >60 msec from 
baseline, the Medical Monitor must be informed. The subject will be asked to return for an 
unscheduled visit within 24 hours and the ECG will be repeated (confirmed), in triplicate (i.e., 
three 10-second ECGs in rapid succession within 1 minute). If the repeat measurements 
confirm that the QTcF is >500 msec or >60 msec from baseline, the subject will be withdrawn 
from treatment with the study treatment and followed until the QTcF value either returns to 
baseline (or as appropriate) or until, in the judgment of the Investigator, further evaluation is 
not clinically indicated. 
If study treatment is discontinued, the subject should continue in the study for all remaining 
scheduled study visits. 
9.1.5 Lupus Disease Activity Assessments 
The SELENA-SLEDAI assesses disease activity within the last 10 days. Twenty-four items 
are scored for 9 organ systems, and summed to a maximum of 105 points. A score of 6 is 
considered clinically significant. See Appendix 6. 
Assessments for SELENA-SLEDAI will be conducted at baseline, Week 24, and Week 52. 
9.1.6 Orelvo Pharmacokinetics 
Blood samples will be taken at Weeks 24 and 52. PK samples will be drawn prior to study 
treatment dosing (trough sample), and at 2 hours post-dose. These samples will be analyzed 
for Orelvo. Should a subject experience an SAE, require a dose modification or be withdrawn 
from treatment, a blood PK sample will be taken (with a trough sample preferred) for later 
determination of drug level. If a subject has discontinued from study drug treatment, further 
PK samples are not required. 
9.2 
Schedule of Assessments 
A detailed schedule of assessments (including all protocol-required assessments, visits, and 
visit windows) is located on the Schedule of Events. No study related assessments will be 
performed (including changes to current medications to meet study eligibility) until the subject 
has provided signed and dated informed consent. Every effort will be made to keep the subject 
within the requested visit schedule. If a subject is seen outside of the visit window listed on the 
Schedule of Events, the reason must be clearly documented in the source notes. The 
Investigator (or designee) should contact Aurinia for assistance with getting the subject’s 
schedule back on track in order to avoid large variances in treatment exposure or to avoid 
delaying overall study timelines. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 62 of 114 
 
9.2.1 Screening Visit Procedures 
The screening visit (Visit 1) will take place within 30 days prior to Visit 2/baseline (Day 1). 
Screening will include provision of informed consent, physical examination including weight, 
and height, medical history (including SLE and LN history), vital signs measurements, 12-lead 
ECG, and review of prior and concomitant medications and entry criteria. Any AEs which 
occur after informed consent will be recorded. Urine samples will be collected for urinalysis 
and urine microscopy; first morning void urine samples (for determination of UPCR) will be 
collected on 2 days during the screening period and must be returned and the results evaluated 
prior to Visit 2. An average of the 2 screening UPCRs will be used as a marker of baseline 
urine protein excretion. Baseline proteinuria level is determined by a mean of 2 first morning 
void urine samples taken during the screening period. The lowest of pre-dose eGFR 
assessments will be used as the marker of baseline renal function. It is recommended that in 
the event that IV corticosteroids are administered during screening, the 2 first morning urine 
voids are to be collected prior to administration of the corticosteroids (see Section 7.2.2.2, 
Corticosteroids). In the case where this is not possible, then the marker of baseline urine protein 
excretion will be based upon the Visit 1 UPCR collection only. This must be discussed with 
the Medical Monitor prior to enrollment. Please note that the results of the 24-hour urine 
collection will have to be available prior to the Baseline Visit.  
Blood samples will be drawn according to Table 2. 
If the subject is from an area where TB is endemic or whose history suggests an increased 
personal risk, e.g., from contact with people with TB or travel to areas with endemic TB, the 
subject will be carefully evaluated for latent or active TB. 
Women of childbearing potential should have a negative serum pregnancy test result before 
randomization. Study treatment cannot be initiated by the physician until a report of a serum 
negative pregnancy test has been obtained. 
If a subject has not met the requirements in Inclusion Criteria #4 due to not having kidney 
biopsy result within the required time frame, a kidney biopsy can be performed as per local 
procedures, after signing the study consent, provided the results can be obtained and reviewed 
prior to randomization. 
9.2.2 Treatment Procedures 
Only subjects who satisfy all of the inclusion and exclusion criteria will be eligible for 
randomization and study treatment. 
Subjects will be fasting for at least 8 hours on the day of randomization and all visit procedures 
must occur prior to the first dose of study treatment on Day 1. The MMF dose required per 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 63 of 114 
 
protocol and IV methylprednisone (or oral corticosteroids) will also be administered at baseline 
before the first dose of Orelvo. 
Subjects will complete all assessments per the Schedule of Events at Day 1, Day 2, and at 
Weeks 2, 4, 8, 12, 16, 20, 24, 30, 36, 42, and 48. IWRS will be accessed to assign study 
treatment to subjects at appropriate visits. 
Adverse events and concomitant medication will be recorded prior to the conduct of other 
study assessments at each visit. 
Assessments at visits during the treatment period include: 
• SF-36 and LupusPRO HRQoL will be answered by the subject, as first study procedure, 
at Baseline, Week 12 and Week 24 
• Physical examination including weight 
• Vital signs 
• ECG at Week 12 and Week 24 
• Blood and urine sample collection for analysis at central laboratory 
• First morning void urine sample collection, except before Day 1 and Day 2 Visits 
• 24-hour urine collection at Week 24 (IMPORTANT: 24-hour urine collection will 
have to begin 2 days prior Week 24 visit in order not to coincide with the first morning 
void sampling due on the day of this visit) 
• Pregnancy testing (serum: Week 24; urine: Day 1 and Weeks 2, 4, 8, 12, 16, 20, 30, 36, 
42, and 48) and immunology 
• AEs 
• Concomitant medication 
• SELENA-SLEDAI will be evaluated at Baseline and Week 24 
• Dispense study treatment – including study treatment and background therapy 
• Returned capsule count and drug accountability 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 64 of 114 
 
• Information for the healthcare resource utilization assessment will be collected and 
recorded at Day 1 and Week 52 
9.2.3 End of Study (or Early Discontinuation) Procedures 
On completion of treatment at Week 52 or earlier if subject is discontinued/withdrawn early, 
all assessments for Visit 15 (end of study/early termination) will be completed per the 
Schedule of Events. See also Section 5.5, Withdrawal of Subjects, for further information on 
withdrawal procedures and criteria. 
The following assessments for the end of study visit will be performed: 
• SF-36 and LupusPro HRQoL 
• Abbreviated physical examination (including body weight) 
• Vital signs 
• Standard 12-lead ECG 
• Blood sample collection for analysis at central laboratory 
• Serum pregnancy testing  
• First morning void 
• 24-hour urine sample collection (IMPORTANT: 24-hour urine collection will have to 
begin 2 days prior to Week 52 visit in order not to coincide with the first morning void 
sampling due on the day of this visit) 
• Concomitant medication 
• AEs 
• SELENA-SLEDAI 
• Returned capsule count and drug accountability 
• Confirmation of completion/discontinuation using IWRS 
• Information for the healthcare resource utilization assessment will be collected and 
recorded 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 65 of 114 
 
9.2.4 Follow-up Procedures 
All subjects who complete the study but do not participate in the continuation study or 
discontinue study treatment before Week 52 will be followed up 4 weeks (±10 days) after their 
last study treatment dose to collect any new AEs and concomitant medications. This visit 
(Visit 16) will be conducted as an in-clinic visit. 
Assessments for the follow-up visit are as follows: 
• Vital signs 
• Blood sample collection for analysis at central laboratory (eGFR) 
• First morning void urine sample collection 
• Concomitant medication 
• AEs 
• Confirmation of completed follow-up visit using IWRS 
9.2.5 Unscheduled Visit 
Unscheduled visits may be performed during the course of the study for safety reasons. An 
unscheduled visit is required 2 weeks after dose reduction at any time during the study. Only 
the data relevant to the purpose of the visit will be collected in the source documents and eCRF. 
An unscheduled visit is requested in the following cases: 
• QTcF value exceeding 500 msec, or an increase >60 msec from baseline, where the 
ECG will be repeated (confirmed) at an unscheduled visit 
• Systolic BP is ≥165 mmHg or diastolic BP is ≥105 mmHg, or confirmed systolic 
BP >130 mmHg or a diastolic BP >80 mmHg 
• Decrease in eGFR >30% compared to baseline, or a confirmed decrease in 
eGFR >20-30% compared to baseline 
• Complete blood count must be performed locally at Weeks 1 and 3 in subjects not 
already taking MMF at the Screening Visit 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 66 of 114 
 
9.3 
Study Specific Assessment Procedures 
9.3.1 Health-related Quality of Life Assessments (HRQoL) 
9.3.1.1 Short Form Health Survey (SF-36) 
The SF-36 HRQoL assessment is a 36-question subject HRQoL questionnaire and is presented 
in Appendix 9. 
9.3.1.2 LupusPRO 
The LupusPRO (v1.7) is a 43-question subject HRQoL questionnaire specific for lupus and is 
presented in Appendix 10. 
9.3.2 Healthcare Resource Utilization Assessment 
The collection of information on healthcare resource utilization will be collected at the time 
points specified in the Schedule of Events (Day 1 and Weeks 24 and 52) and documented in 
the EDC system. This information will be collected via interview of the subject by the study 
staff and entered into the EDC system. General information collected may include: 
• Type of insurance coverage 
• Number of visits to ANY health care professionals (HCP), other than study doctor  
• Types of HCP visited (specialists versus primary care)  
• Time spent on visits 
• Diagnostic tests performed  
• Time spent by caregivers assisting patient with HCP visits (can ask general question if 
subject required a family member or other person to assist them to attend the visit) 
• Prescriptions issued, filled 
• Community services used 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 67 of 114 
 
10. EVALUATION, RECORDING AND REPORTING OF AES AND 
SAES 
10.1 Definitions 
10.1.1 Adverse Event 
Any untoward medical occurrence in a subject administered a pharmaceutical product and 
which does not necessarily have a causal relationship with this treatment is an AE. An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal (investigational) 
product, whether or not related to the medicinal (investigational) product. 
10.1.2 Adverse Drug Reaction 
In the pre-approval clinical experience with a new medical product or its new usages, 
particularly as the therapeutic dose(s) may not be established, all unintended responses to a 
medicinal product related to any dose should be considered adverse drug reactions (ADRs). 
The phrase “responses to a medicinal product” means that a causal relationship between a 
medicinal product and an AE is at least a reasonable possibility, i.e., the relationship cannot be 
ruled out. 
10.1.3 Serious Adverse Event 
An SAE (experience) or reaction is an untoward medical occurrence that at any dose meets 
1 or more of the following criteria: 
• Results in death (Note: death is an outcome, not an event) 
• Is life-threatening (Note: the term “life-threatening” refers to an event in which the 
subject was at immediate risk of death at the time of the event; it does not refer to an 
event which could hypothetically have caused a death had it been more severe) 
• Requires in-patient hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability/incapacity 
• Results in a congenital anomaly/birth defect 
• Is a medically important event or reaction 
The definitions and reporting requirements of International Council for Harmonisation (ICH) 
Guidelines for Clinical Safety Data Management, Definitions, and Standards for Expedited 
Reporting, Topic E2 will be adhered to. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 68 of 114 
 
Medical and scientific judgment must be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events that may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the subject or may 
require intervention to prevent one of the other outcomes listed in the definition above. These 
will also usually be considered serious. 
Hospitalizations for elective or previously scheduled surgery for pre-existing conditions, 
which have not worsened after initiation of treatment, will not be classed as SAEs. Previously 
scheduled hospitalizations must be documented in the subject’s source documents before the 
subject signed the informed consent form (ICF). A kidney biopsy performed as part of the 
study to verify eligibility will not be considered an SAE. Any complication experienced during 
a kidney biopsy procedure resulting in hospitalization or a prolongation of the hospitalization 
requires SAE reporting. 
10.1.4 Suspected Unexpected Serious Adverse Reaction  
Any ADR that is both serious and unexpected (per the IB) that, based on the opinion of the 
Investigator or Aurinia, is felt to have a reasonable suspected causal relationship to a medicinal 
product is a suspected unexpected serious adverse reaction. 
10.2 Adverse Event Descriptors 
10.2.1 Intensity/Severity Categorization 
The term “severe” is often used to describe the intensity (severity) of a specific event (as in 
mild, moderate, or severe myocardial infarction); however the event itself may be of relatively 
minor medical significance (such as severe headache). This is not the same as “serious,” which 
is based on subject/event outcome or action criteria usually associated with events that pose a 
threat to a subject’s life or functioning. Seriousness (not severity) serves as a guide for defining 
regulatory reporting obligations. 
In general, the intensity of a particular AE to be recorded is the worst intensity experienced by 
the subject during the course of the event. The medical assessment of intensity will be 
determined by using the following definitions: 
Mild: 
The AE is easily tolerated and does not interfere with usual activity. 
Moderate: 
The AE interferes with daily activity, but the subject is still able to function. 
Severe: 
The AE is incapacitating and the subject is unable to work or complete usual 
activity. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 69 of 114 
 
10.2.2 Causal Relationship Categorization 
An Investigator who is qualified in medicine must make the determination of relationship to 
the study treatment for each AE and SAE. The Investigator must decide whether, in his or her 
medical judgment, there is a reasonable possibility that the event may have been caused by the 
study treatment. If there is no valid reason for suggesting a relationship, then the AE/SAE must 
be classified as not related. Otherwise, if there is any valid reason, even if undetermined or 
untested, for suspecting a cause-and-effect relationship between the study treatment and the 
occurrence of the AE/SAE, then the AE/SAE will be considered related. For SAEs, the 
Investigator must provide a brief comment explaining the rationale of his/her assessment of 
causal relationship on the SAE reporting form. 
The following additional guidance may be helpful: 
Term 
Relationship 
Definition 
Related 
Yes 
The temporal relationship of the clinical event to study drug administration 
indicates a causal relationship, and other drugs, therapeutic interventions or 
underlying conditions do not provide a sufficient explanation for the observed 
event. 
Not related 
No 
The temporal relationship of the clinical event to study drug administration 
does not indicate a causal relationship, or other drugs, therapeutic 
interventions or underlying conditions provide a sufficient explanation for the 
observed event. 
 
If the causal relationship between an AE/SAE and the study treatment is determined to be 
“related”, the event will be considered to be related to study treatment for the purposes of 
expedited regulatory reporting. In circumstances where the Investigator has not yet provided 
his/her assessment about the relationship, the event will be considered as “related” and qualify 
for expedited regulatory reporting. 
10.2.3 Outcome Categorization 
Outcome may be classified as recovered without sequelae; recovered with sequelae; improved; 
worsened; ongoing; ongoing at end of study; fatal; or unknown. If the outcome is reported as 
recovered with sequelae for an SAE, the Investigator should specify the kind of sequelae on 
the SAE reporting form. SAEs that are ongoing at the time of death will have an outcome of 
“unknown” recorded. SAEs resulting in a fatal outcome will have an outcome of “fatal” 
recorded. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 70 of 114 
 
10.2.4 Symptoms of the Disease Under Study 
Symptoms of the disease under study will not be classed as AEs as long as they are within the 
normal day-to-day fluctuation of the disease. An explanation of these circumstances must be 
written in the source documents. 
Worsening of the symptoms however, will be recorded as an AE, and clearly marked as 
worsening or by the subject’s worst observed intensity. 
10.2.5 Clinical Laboratory Evaluations 
A change in the value of a safety laboratory investigation can represent an AE if the change is 
clinically relevant in the opinion of the Investigator or if, during treatment with the study 
treatment, a shift of a parameter is observed from a normal value to a pathological value, or a 
further worsening of an already pathological value. 
If, at the end of the treatment phase, there are pathological laboratory values which were not 
present at baseline, further clinical or laboratory investigations will be performed until the 
values return to within reference range or until a plausible explanation (e.g., concomitant 
disease) is found for the pathological laboratory values. 
If the Investigator considers such an AE as serious it must be reported as an SAE. 
10.2.6 Abuse, Misuse, Overdose and Medication Error 
All AEs of special interest such as study treatment abuse, misuse, overdose, and medication 
error have to be documented in the subject’s eCRF and source documentation. If any 
occurrence of abuse, misuse, overdose, or medication errors leads to any event that fulfils any 
seriousness criteria, the event has to be reported as an SAE. 
10.3 Reporting Procedure for AEs, SAEs, and Pregnancy 
10.3.1 Adverse Events 
All AEs either observed by the Investigator or one of his/her medical collaborators, or reported 
by the subject spontaneously, or in response to a direct question, will be noted in the AE section 
of the subject's eCRF and source documentation. This applies to all AEs regardless of 
presumed relationship to the study treatment. Adverse events leading to discontinuation of 
study treatment must be collected. 
If any AE is reported, the date of onset, relationship to study treatment, any action taken, date 
of resolution (or the fact that it is still continuing or has become chronic), outcome, and whether 
the AE is serious or not, will be recorded. Use of colloquialisms and abbreviations should be 
avoided. Only 1 AE term should be recorded in the event field on the AE eCRF. Where 
possible, the Investigator should report a diagnosis rather than signs and symptoms or 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 71 of 114 
 
abnormal laboratory values. However, if a constellation of signs and/or symptoms cannot be 
medically characterized as a single diagnosis or syndrome at the time of reporting, each 
individual event should be recorded on the AE eCRF. If a diagnosis is subsequently 
established, all previously reported AEs based on signs and symptoms should be nullified and 
replaced by one AE report based on the single diagnosis, with a starting date that corresponds 
to the starting date of the first symptom of the eventual diagnosis. 
The AE reporting period begins at the time the ICF is signed by the subject. The AE reporting 
period ends at Visit 15 (if the subject participates in the continuation study) or the study 
follow-up visit (Visit 16), if the subject does not participate in the continuation study. Adverse 
events persisting at the time of study completion will be followed by the Investigator through 
contact with the subject until resolution or stabilization has occurred (or the subject is lost to 
follow-up and cannot be contacted) and recorded in the source documents. If the subject reports 
an AE, it is the Investigator’s responsibility to acquire sufficient information in order to assess 
causality. This may require additional laboratory testing, physical examinations, telephone 
contacts, etc. In circumstances where the Investigator is unable to make contact with the 
subject, the Investigator must provide a written statement to Aurinia confirming that the subject 
is lost to follow-up. 
In order to avoid bias in eliciting AEs, subjects should be asked a non-leading question, such 
as “How are you feeling?” It is also important to question the subject in a non-leading way 
about changes in their health or concomitant medication usage since their last visit. This 
information should be collected prior to completion of assessments at all study visits. In 
addition, any symptoms/conditions reported during assessments and deemed to be clinically 
significant by the Investigator will be considered AEs. 
10.3.2 Serious Adverse Events 
All SAEs occurring after the signing of the ICF will be reported to 
 
within 24 hours of the Investigator, designee, or site staff’s knowledge of the event regardless 
of relationship to study treatment. All SAEs are to be reported on the eCRFs. 
In the event that the site experiences a temporary disruption of the EDC system a back-up 
paper SAE Reporting Form will be available for site staff to complete. 
• Site staff will complete the paper SAE report form and e-mail it within 24 hours to the 
following address: 
 
• Only in cases where the email system is unavailable, site staff will send the SAE by fax 
to: 
 (US) and 
 (Outside US). 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 72 of 114 
 
If notification is made via email or fax, site staff must enter the SAE information into the 
electronic data capture (EDC) system as soon as the system becomes available. 
All SAEs, regardless of causality, will be reported from the time the ICF is signed until 30 days 
following the last study visit or 30 days after last study treatment administration in subjects 
who withdraw or discontinue prior to study completion. No formal study visit is required but 
Investigators must report any SAEs that occur during this 30 day period on the eCRF. If the 
Investigator has not seen the subject at a clinic visit at the end of the reporting period, the 
Investigator must make reasonable efforts to contact the subject to inquire about SAEs. 
All recorded SAEs, regardless of relationship to study treatment, will be followed up until 
resolution, stabilization, or the subject is lost to follow-up and cannot be contacted. In 
circumstances where the Investigator is unable to make contact with the subject, the 
Investigator must provide a written statement to Aurinia confirming that the subject is lost to 
follow-up. 
Any SAE considered to have a causal relationship (i.e., “related”) to the study treatment and 
discovered by the Investigator at any time after the study will be reported. A rationale for the 
assessment of a causal relationship must be provided by the Investigator. Any safety 
information that is obtained after the Follow-up Visit (Visit 16) will be documented in the 
safety database only. 
A death occurring during the study or which comes to the attention of the Investigator within 
30 days after the last study visit (including the Follow-up Visit) or until 30 days after the last 
study treatment administration, whichever is longer, whether considered treatment-related or 
not, must be reported to Aurinia. If the subject died, the SAE report should include the cause 
of death as the event term and whether or not the death was related to study treatment, as well 
as the autopsy findings, if available. Preliminary reports will be followed by detailed 
descriptions which will include copies of hospital case reports, autopsy reports/certificates and 
other documents when requested and applicable. 
Additional follow-up information must be reported in the eCRF within 24 hours of awareness 
following Investigator (or site) awareness of the information. The Investigator should not delay 
reporting an SAE in order to obtain additional information. Additional information, when 
available, should be reported to 
 by the reporting procedures 
described above. 
The Investigator is encouraged to discuss with the study Medical Monitor when the issue of 
seriousness is unclear or questionable. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 73 of 114 
 
An investigator who receives an investigator safety report describing an SAE or other specific 
safety information (e.g., summary or listing of SAE) from the sponsor will file it along with 
the IB and will notify the IRB/IEC, if appropriate according to local requirements. 
The sponsor or its representative will be responsible for determining and, in turn, reporting 
SAEs to regulatory authorities according to the applicable regulatory requirements. 
10.3.3 Pregnancy 
Pregnancy occurring in a female subject or in the partner of a male subject should be reported 
to 
 within 24 hours of becoming aware of the event using the 
pregnancy eCRF. The Investigator should counsel the subject, and in the case of a male subject, 
the subject’s partner, discuss the risks of continuing with the pregnancy and the possible effects 
on the fetus. A female subject must immediately inform the Investigator if she becomes 
pregnant during the study. Monitoring of the pregnancy in a female subject should continue 
until conclusion of the pregnancy. In case of a pregnancy in the partner of a male subject, the 
Investigator should obtain informed consent of the pregnant partner prior to monitoring of the 
pregnancy. 
Women who have a positive pregnancy test during the study will be withdrawn from the study 
treatment and the procedures for withdrawal will be completed. The Medical Monitor must be 
contacted immediately to break the blind (if applicable). 
All pregnancies, subject or partner of a subject, that occur during the study or come to the 
attention of the Investigator within 30 days after the last study visit (including the Follow-up 
Visit) or until 30 days after last study treatment administration, whichever is longer, must be 
reported to 
 by the reporting procedures described above. 
The outcome of all such pregnancies (including normal births) should be followed up and 
documented, even if the subject was withdrawn from the study. Every effort should be made 
to gather information regarding the pregnancy outcome until 90 days (or otherwise as 
appropriate) post-partum. It will be the responsibility of Aurinia, together with the appropriate 
support of the Investigator, to obtain this information. 
Complications of pregnancy such as abortion (spontaneous or induced), premature birth, or 
congenital abnormality are considered SAEs and should be reported following the reporting 
procedures as outlined in Section 10.3.2, Serious Adverse Events. In the event that the site 
experiences a temporary disruption of the EDC system, a back-up paper Pregnancy Reporting 
Form will be available for site staff to complete. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 74 of 114 
 
11. CLINICAL ENDPOINTS COMMITTEE 
A CEC will be constituted to adjudicate the following renal response (primary efficacy 
endpoint) parameters for subjects in this study: 
• UPCR of ≤0.5 mg/mg, and 
• eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of >20%, 
and 
• Received no rescue medication for LN (see Section 7.8, Prohibited Therapy and 
Concomitant Treatment), and 
• Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in 
total during Weeks 44 through 52, just prior to the renal response assessment 
The CEC will adjudicate renal response by reviewing blinded data. Aurinia will establish a 
charter document explaining the working procedures and responsibilities of the CEC. All 
adjudication decisions of the CEC will be appropriately documented. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 75 of 114 
 
12. DATA AND SAFETY MONITORING BOARD PROCEDURES 
A DSMB will be constituted to protect the safety of study participants. The DSMB will receive 
blinded eCRF data in the form of tables and listings (prepared by an independent statistician), 
and review subject status changes and dosing decisions (where appropriate). Where 
appropriate, the DSMB may receive unblinded data (on a subject level or treatment group 
level) that should be reviewed in a closed session. The data should include, but is not limited 
to, demographics, subject enrollment, baseline characteristics, AE data, SAE data (by severity 
and causality), laboratory data, dose adjustments, protocol adherence, and subject withdrawals. 
The DSMB will evaluate the progress of the study, assess data quality and timeliness, 
participant recruitment, accrual and retention, and participant benefit versus risk. In addition 
the DSMB will monitor external factors relevant to the study, for example scientific and 
therapeutic developments that may affect participant safety or ethical status. Based on the 
observed benefits or adverse effects, the DSMB will make recommendations to Aurinia 
concerning continuation, termination, or modifications of the study. 
Aurinia will establish a charter document explaining the working procedures and 
responsibilities of the DSMB. All deliberations and decisions of the DSMB will be 
appropriately documented. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 76 of 114 
 
13. STATISTICAL ANALYSIS 
13.1 Statistical Methods 
Complete details of the statistical and analytical methods will be provided in a formal 
Statistical Analysis Plan (SAP), which will be finalized prior to the database lock. A general 
description of the planned methods is provided below. Any deviation from the SAP will be 
noted and explained in the clinical study report. 
13.2 Sample Size and Power Calculations 
The total sample size will be 324 subjects (162 subjects per treatment arm). This is based on 
the following assumptions: 
• A two group continuity corrected Chi square test with a 0.05 two-sided significance 
level will have 80% power to detect the difference between a placebo response rate of 
20.0% and a Orelvo response rate of 34.4% (odds ratio=2.1) when the sample size in 
each group is 162 (total N=324). 
• The effect of withdrawals will be investigated. Subjects withdrawing for any reason 
will be counted as non-responders in the primary analysis and therefore no adjustment 
of sample size for withdrawals is necessary. 
• The impact of withdrawals on primary endpoint will be investigated with a tipping 
point analysis. 
Table 3 shows the Orelvo response rates required to maintain a minimum 80% power at the 
planned sample size for given placebo response rates. These response rates all lead to odds 
ratios of around 2, which is a clinically relevant effect. 
Table 3 
Orelvo Response Rates Required to Maintain a Minimum 80% Power 
Placebo Response Rate 
Orelvo Response Rate 
Odds Ratio 
15% 
28.4% 
2.25 
19% 
33.2% 
2.12 
25% 
40% 
2.0 
Note: 
Based on the planned sample size of 324 subjects (162 subjects per treatment arm). 
 
13.3 Populations 
13.3.1 Intent-to-Treat Set 
The intent-to-treat set will be based on intent-to-treat (ITT) principles and will consist of all 
subjects who are randomized to treatment. This group will be analyzed based on the treatment 
to which the subject was randomized. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 77 of 114 
 
13.3.2 Safety Set 
The safety set will consist of all randomized subjects who have taken at least 1 dose of study 
treatment. The subjects in this group will be analyzed based on the treatment they received. 
Subjects who receive treatment from more than 1 arm will be assigned to the Orelvo arm. 
13.3.3 Per-protocol Set 
The per-protocol set will consist of all subjects eligible from the ITT population who do not 
have any major protocol violations. Major protocol violations will be defined in the statistical 
analysis plan and fully assessed at the subject level prior to unblinding of the study. 
13.4 Background and Demographic Characteristics 
Demographic and clinical disease characteristics will be summarized by treatment arm in a 
descriptive manner but no statistical tests will be performed.  
13.5 Study Treatment 
Compliance to the study treatment will be determined by dividing the number of softgel 
capsules taken by the expected number of softgel capsules to be taken (based on prescribed 
dose) over the subject’s participation in the study. 
Results will be summarized by means of descriptive statistics (n, mean, standard deviation, 
median, minimum, and maximum) and frequency tables, by treatment arm.  
13.6 Concomitant Therapy 
All concomitant medications will be coded by the WHO Anatomical Therapeutic Chemical 
Drug Reference List classification. The version used will be provided in the clinical study 
report. 
13.7 Efficacy Evaluations 
13.7.1 Primary Endpoint 
The primary endpoint is the number of subjects showing renal response at 52 weeks. Renal 
response at Week 52 will be adjudicated by the CEC based on the following parameters: 
• UPCR of ≤0.5 mg/mg, and 
• eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of >20%, 
and 
• Received no rescue medication for LN (see Section 7.8, Prohibited Therapy and 
Concomitant Treatment), and 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 78 of 114 
 
• Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in 
total during Weeks 44 through 52, just prior to the renal response assessment 
Subjects who withdraw from the study prior to the Week 52 assessment will be defined as non-
responders. 
13.7.2 Secondary Endpoints 
13.7.2.1 
Key Secondary Endpoints 
• Time to UPCR of ≤0.5 mg/mg  
• Partial renal response as defined by 50% reduction from baseline UPCR at Weeks 24 
and 52 
• Time to 50% reduction in UPCR from baseline 
• Renal response at Week 52 (based on definition of primary endpoint) 
• Duration of UPCR ≤0.5 mg/mg 
• Proportion of subjects experiencing a confirmed >30% decrease from baseline in 
eGFR at each timepoint 
13.7.2.2 
Other Secondary Endpoints 
• Change from baseline in UPCR at each time point 
• Change from baseline in serum creatinine, urine protein, and eGFR 
• Change from screening in immunology parameters (C3, C4, and dsDNA) at Weeks 24 
and 52 
• Renal response with low-dose steroids (defined as renal response in the presence of 
corticosteroids of ≤2.5 mg/day between Weeks 16 to 24 and Weeks 44 to 52) 
• Change from baseline in HRQoL at Weeks 12, 24, and 52 
• Health Resource Utilization at Weeks 24 and 52 
• Change from baseline in the SELENA-SLEDAI Index score at Weeks 24 and 52 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 79 of 114 
 
13.8 Statistical and Analytical Methods 
13.8.1 Primary Efficacy Analysis 
The primary efficacy endpoint is the renal response at Week 52 (Section 13.7.1, Primary 
Endpoint).  
The study null hypothesis H0 and alternative hypothesis H1 are as follows: 
H0: There is no difference in renal response between Orelvo and placebo. 
H1: There is a difference in renal response between Orelvo and placebo. 
The null hypothesis H0 will be rejected in favor of H1 if there is evidence at the 5% significance 
level using a 2-sided test.  
The primary efficacy analysis will be conducted on the ITT set using logistic regression with 
terms for treatment, baseline UPCR, biopsy class, and MMF use at baseline. The results being 
expressed as an odds ratio (and associated two-sided 95% CI) for Orelvo compared to placebo. 
Odds ratios greater than unity show the odds of response are greater for Orelvo than for placebo 
and therefore indicate a benefit of the Orelvo treatment arm. 
13.8.2 Sensitivity Analyses 
The following sensitivity analyses will be performed: 
• Renal response at Week 52 will be analyzed using a logistic regression including only 
a term for treatment. This analysis will be performed on the ITT set.  
• The analysis described in Section 13.8.1, Primary Efficacy Analysis will be repeated 
for the per protocol analysis set. 
• The impact of withdrawals on primary endpoint will be investigated with a tipping 
point analysis. 
13.8.3 Secondary Efficacy Analysis 
All the secondary efficacy analyses will be performed on the ITT set.  
13.8.3.1 
Response Endpoints 
The following secondary endpoints will be analyzed using logistic regression as outlined in 
Section 13.8.1, Primary Efficacy Analysis. These analyses will be conducted on the ITT 
population and will incorporate baseline variables within the model as appropriate. 
• Renal response at Week 52 (based on definition of primary endpoint) 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 80 of 114 
 
• Partial renal response as defined by 50% reduction from baseline in UPCR at Weeks 24 
and 52 
• Renal response with low-dose steroids (defined as renal response in the presence of 
corticosteroids of ≤2.5 mg between Weeks 16 to 24 and Weeks 44 to 52) 
13.8.3.2 
Time to Endpoints 
The following secondary endpoints: time to renal response, time to partial renal response, and 
duration of UPCR ≤0.5 mg/mg will be analyzed by comparing the survivor function between 
treatment arms. It will be estimated using Kaplan-Meier methodology and will be presented as 
a plot showing a line for each treatment group. Median time-to-event along with two-sided 
confidence intervals will be displayed.  
Cox’s proportional hazards model will be performed to assess the significance of the 
differences between treatment arms. The model will include terms for treatment, baseline 
UPCR, biopsy class, and MMF use at baseline. Estimates of the treatment effects will be 
expressed as hazard ratios (and associated 95% CI) for Orelvo relative to placebo. Hazard 
ratios greater than unity show the hazard to be greater for Orelvo than for placebo and therefore 
indicate that the events in question generally occur earlier on active Orelvo. 
The log-rank test and Cox’s proportional hazards model assume that the hazard ratio is constant 
over time. This assumption will be checked graphically by plotting log-log survivor functions 
for the treatment groups. It should be noted that modest deviations from the proportionality 
assumption generally will not invalidate inference. 
13.8.3.3 
Change from Baseline Endpoints 
The following secondary endpoints will be analyzed using a Mixed Effect Model Repeated 
Measures analysis with treatment arm, visit, treatment by visit interaction, biopsy class, and 
MMF use at baseline included as a covariate in the model. Results will be expressed as 
differences between treatment arms (along with the associated 95% CI).  
• Change from baseline in UPCR at each visit 
• Change from baseline in serum creatinine, urine protein, and eGFR at each visit 
• Change from screening in immunology parameters (C3, C4, and anti-dsDNA) at 
Weeks 24 and 52 
• Change from baseline in HRQoL at Weeks 12, 24, and 52 
• Change from baseline in the SELENA-SLEDAI score at Weeks 24 and 52 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 81 of 114 
 
13.8.3.4 
Health Resource Utilization 
• Health Resource Utilization at Weeks 24 and 52. Key aspects will be summarized by visit 
and changes over time will be explored. 
13.8.4 Multiplicity 
An overall type 1 (false-positive) error rate of 5% for the efficacy endpoints will be maintained 
so that no statistical significance for the secondary efficacy endpoints will be claimed unless 
the principal analysis of the primary efficacy endpoint using the ITT set is statistically 
significant at the 5% level. The Hochberg step-up method will be used to adjust for multiple 
comparisons amongst key secondary endpoints and maintain the overall type 1 error rate [21]. 
Data from all analyses, regardless of the level of significance, will be presented for review.  
13.9 Safety Evaluations 
Specific safety endpoints are as follows: 
• Biochemical (including liver function tests) and hematological laboratory tests 
• AE profile and routine biochemical and hematological safety parameters 
• Vital signs (BP, HR, temperature) at specific time points and change from baseline 
• Standard 12-lead ECGs change from baseline 
• Discontinuations from treatment 
• Concomitant medications 
Laboratory values, vital signs, and other safety parameters providing numeric data will be 
summarized by treatment arm, visit, and as change from baseline. 
Adverse events will be coded using the latest available version of the Medical Dictionary for 
Regulatory Activities, the version of which will be provided in the clinical study report. 
Treatment-emergent adverse events will be summarized by treatment arm, system organ class, 
and preferred term. SAEs, SAEs that led to death, and SAEs/AEs that led to withdrawal will 
also be summarized and listed. 
Only AEs which started on or after the date of first dose of study treatment will be considered 
TEAEs, though all AEs after informed consent will be recorded. SAEs occurring at any time 
after informed consent will be summarized. All concomitant medications will be summarized. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 82 of 114 
 
Details of these and other analyses will be provided in the SAP. 
All study data analyses involving laboratory values will be based on results from the central 
laboratory. 
13.10 Interim Analyses 
There are no planned interim analyses. 
13.11 Other Evaluations 
13.11.1 Pharmacokinetics 
Estimates of Orelvo exposure derived from this analysis will be examined for possible 
relationship to measures of efficacy and safety. Full details will be described in a separate 
analysis plan. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 83 of 114 
 
14. ETHICAL CONDUCT OF THE STUDY 
The study will be conducted according to the principles of the World Medical Association’s 
Declaration of Helsinki [21] and the ICH guidelines for GCP [23]. Aurinia will ensure that the 
study complies with all local, federal, and country regulatory requirements. 
The Investigator must ensure the confidentiality of all subjects participating in the study. 
All anonymous data remains the property of Aurinia. 
14.1 Informed Consent 
The ICF used for the study must comply with the Declaration of Helsinki, federal regulations, 
and ICH guidelines; and must have been approved by the Institutional Review Board 
(IRB)/Ethics Committee (EC)/Independent Ethics Committee (IEC) prior to use. The 
Investigator or an authorized associate must explain the nature of the study and the treatment 
in such a manner that the subject is aware of potential benefits and risks. Subjects must also be 
informed that participation is voluntary and that they may withdraw from the study at any time, 
without prejudice. Subjects must be provided sufficient time to consider participation, 
including discussion with family members prior to signing the ICF. Documentation of the 
discussion and the date of informed consent must be recorded in the source documentation. 
After signing the ICF, subjects will be enrolled into the study and assigned a subject 
identification number that will be used on all subject documentation. 
The informed consent can be signed up to 30 days before the screening Visit 1. If more than 
30 days elapses between date of consent and the screening Visit 1, the subject should be asked 
to re-sign and date the consent form to confirm continued interest in study participation. 
14.2 Institutional Review Board or EC/IEC 
The protocol, any protocol amendments and consent form for the proposed clinical study and 
any other documents required by the local IRB/EC/IEC must be submitted by the Investigator 
for review and approval to the IRB/EC/IEC. The Investigator must also ensure that the 
IRB/EC/IEC reviews the progress of the study on a regular basis and, if necessary, renews its 
approval of the study per local requirements. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 84 of 114 
 
15. QUALITY CONTROL AND QUALITY ASSURANCE 
The Investigator must ensure that all study-related site source data, study-related documents, 
and reports will be available, and that the provision of direct access for monitoring and auditing 
by Aurinia or its designees will be permitted. In addition, the Investigator must ensure that all 
study-related site source data, study-related documents, and reports will be made available for 
inspection by the appropriate Regulatory Authority and review by the IRB/EC/IEC. 
The Investigator is responsible for notifying Aurinia in advance of an impending regulatory 
inspection. He/she may request that Aurinia provide support for preparation, if necessary. The 
Investigator is required to provide updates to Aurinia on the ongoing activities during the 
inspection, respond to any citations/objectionable findings (i.e., U.S. Food and Drug 
Administration Form 483) and to share any follow up responses from the Regulatory 
Authority. 
Accurate and reliable data collection will be assured by verification and cross-check of the 
eCRFs against the Investigator’s records by the Study Monitor (source document verification). 
The Monitor will also review the Investigator’s drug accountability records to ensure that the 
drug supplies are stored and dispensed appropriately. A comprehensive validation program 
will verify the data and queries will be generated for resolution by the Investigator. Throughout 
the study, Aurinia or its designates may review data as deemed necessary. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 85 of 114 
 
16. ADMINISTRATIVE PROCEDURES 
16.1 Sponsor’s Responsibilities 
16.1.1 Study Supplies 
Sites will be provided with all supplies required to manage this study. This will include but not 
be limited to the following: 
• Investigator file(s) (for filing of all study related documentation). 
• Kits for collection, storage, and transportation of applicable samples required for 
central laboratories. This will also include all applicable guidelines and contact details. 
• Contact list of all relevant study personnel. 
• eCRF and completion guidelines (or equivalent electronic data capture system). 
• Study reference manual. 
• All study forms (e.g., SAE, pregnancy, drug accountability, etc.). 
16.1.2 Insurance 
Aurinia confirms that it carries liability insurance which protects non-employee physicians or 
Investigators/study staff against claims for which they may become liable as a result of 
damages caused by Aurinia products used in clinical studies. Insurance coverage is not 
extended to damages that the Investigators or third parties may suffer by reason of acts of 
commission or omission on the part of such Investigators or third parties and that are not in 
accordance with accepted common medical practices (lege artis procedures). Aurinia will 
reimburse the subject for all study-related injuries provided that the injury does not arise from 
the subject’s misuse of the study treatment or failure to follow the Investigator’s instructions. 
16.1.3 Study Monitoring 
The study will be monitored by representatives of Aurinia (or designee, which may include a 
contract research organization). If not monitored by Aurinia, documentation of delegation will 
be described in the Clinical Trial Agreement. It is understood that the responsible Monitor will 
contact and visit the Investigator regularly and will be allowed, on request, to inspect the 
various records of the study (eCRFs and other pertinent data) provided that subject 
confidentiality is maintained in accordance with local requirements. 
It will be the Monitor's responsibility to inspect the eCRFs at regular intervals throughout the 
study (frequency outlined in a separate procedural document), to verify the adherence to the 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 86 of 114 
 
protocol and the completeness, consistency, and accuracy of the data being entered on them. 
The Monitor must have access to laboratory test reports and other subject records needed to 
verify the entries on the eCRF. The Investigator (or his/her deputy) agrees to co-operate with 
the Monitor to ensure that any problems detected in the course of these monitoring visits are 
resolved. 
16.2 Investigator’s Responsibilities 
16.2.1 Reporting and Recording of Data 
All required study data must be entered in the eCRF created for the study. Training on the 
system will be provided to all sites, including instructions on how to address missing data, 
corrections, query procedures, and electronic signatures. Only individuals who are identified 
on the authorized signature page may enter/correct data in the eCRF. For those subjects who 
withdraw before completion of the study, all available efficacy and safety data must be entered 
in the eCRF. Incomplete or inconsistent data on the eCRF will result in data queries addressed 
to the Investigator for resolution. 
16.2.2 Investigator Training 
All Investigators and their study personnel will receive training regarding the study procedures, 
study treatments, and GCP/regulations specific to the conduct of clinical studies. This training 
will take place prior to enrollment of the first subject at the study site, and must be documented 
and filed in the Investigator’s Study Site File. 
16.2.3 Source Documentation 
The Investigator must maintain adequate and accurate records to enable the conduct of the 
study to be fully documented and the study data to be subsequently verified. 
Subject clinical source documents would include subject hospital/clinic records, physician’s 
and nurse’s notes, appointment book, original laboratory reports, ECG, X-ray, pathology and 
special assessment reports, signed ICFs, consultant letters, and subject screening and 
enrollment logs. These are to be separate and distinct from eCRFs. All data for the study must 
be available in source documentation, including oral and written communication with the 
subject regarding the study treatment (including the risks and benefits of the study). The date 
of informed consent must be recorded in the source documentation. 
The Investigator must arrange for the retention of all study documentation (such as eCRFs, 
research files, and master files) for the duration specified in their respective site contract. The 
Investigator must keep these documents on file after completion or discontinuation of the study 
according to local governing guidelines. Archived data may be held electronically, provided 
that a back-up copy exists and that a hard copy can be generated if required. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 87 of 114 
 
The Investigator must inform Aurinia immediately if any documents are lost, to be transferred 
to a different facility, or to be transferred to a different owner. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 88 of 114 
 
17. PROCEDURE FOR MODIFICATION OF PROTOCOL OR 
PREMATURE TERMINATION OF THE STUDY 
17.1 Protocol Waivers, Deviations and Violations 
Protocol waivers shall not be permitted. 
The Investigator should not implement any deviation from, or changes of the protocol without 
written agreement from Aurinia and prior documented approval/favorable opinion from the 
IRB/IEC of an amendment, except where necessary to eliminate an immediate hazard(s) to 
study subjects, or when change(s) involves only logistical or administrative aspects of the 
study. If the Investigator must implement a deviation from, or a change of, the protocol to 
eliminate an immediate hazard(s) to study subjects without prior written approval, the 
implemented deviation or change and the reasons for it should be submitted in a timely manner 
to Aurinia and to the IRB/IEC as required by applicable local requirements. 
The Investigator, or person designated by the Investigator, will document and record the 
preventative and/or corrective measures for any deviation from the approved protocol. 
Accidental deviations from the protocol including violations of inclusion/exclusion criteria 
will be assessed as minor or major on a case-by-case basis. The criteria describing the 
deviation(s) and how they will be handled will be documented in the SAP. 
Any amendment to the protocol requires written approval/favorable opinion by the IRB/IEC 
prior to its implementation, unless there are overriding safety reasons. 
In some instances, an amendment may require a change to the ICF. The Investigator must 
receive an IRB/IEC approval/favorable opinion concerning the reviewed document prior to 
administering to study subjects. 
17.2 Study Termination 
Aurinia reserves the right to terminate the study in its entirety or at a site at any time. Reasons 
for termination may include, but are not limited to the following: unsatisfactory subject 
enrollment with respect to quality and/or quantity, site is unable to comply with the 
requirements of the protocol or GCP, or data recording is inaccurate and/or incomplete. 
In terminating the study, Aurinia and the Investigator will assure that adequate consideration 
is given to the protection of the subjects. Both parties will arrange the procedures on an 
individual basis after review and consultation and in accordance with the study contract. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 89 of 114 
 
18. POLICY FOR PUBLICATION AND PRESENTATION OF DATA 
Aurinia is committed to the timely communication of data from clinical research trials, 
following the Pharmaceutical Research and Manufacturers of America principles [24]. Where 
possible, authorship will be agreed at the beginning of the study. The authors will form a 
publication committee and this committee will propose and develop appropriate scientific 
manuscripts or abstracts from the study data. Investigators may not present or publish partial 
or complete study results individually. Any manuscript or abstract proposed by the 
Investigators must be reviewed and approved in writing by Aurinia before submission for 
publication. Names of all Investigators participating in the study will be included in the 
publication. 
The publication committee for a study will comprise of authors selected in adherence with the 
International Committee of Medical Journal Editors criteria [25] for authorship. If studies are 
multicenter, it may be appropriate to assign group authorship. 
In addition, certain Aurinia employees involved in the design and conception of the protocol, 
study management and data analysis and interpretation are qualified authors and will be 
included in the publication committee. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 90 of 114 
 
19. REFERENCES 
1. 
Ward MM. Changes in the incidence of end stage renal disease due to lupus nephritis 
in the United States, 1996-2004. J Rheumatol. 2009 Jan;36(1):63-7. 
2. 
Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli 
MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing 
low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010 
Jan;69(1):61-4. Epub 2009 Jan 20. 
3. 
Lee YH, Woo J-H, Choi SJ, Ji JD, Song GG. Induction and maintenance therapy for 
lupus nephritis: a systematic review and meta-analysis. Lupus. 2010 May; 19(6):703-
10. Epub 2010 Jan 11. 
4. 
Study WX17801. A prospective, randomized, active controlled, parallel group, multi-
center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in 
inducing response and maintaining remission in subjects with lupus nephritis (LN). 
Final report. Victoria (BC): Aspreva Pharmaceuticals Corporation; 2008 May 6. Report 
No.: 1024493. 
5. 
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al; Aspreva 
Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide 
for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May;20(5):1103-
12. Epub 2009 Apr 15. 
6. 
Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease 
progression. Kidney Int. 1997;51:2-15. 
7. 
Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al; 
Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and 
adverse outcomes. JAMA. 2010 Feb 3;303(5):423-9. 
8. 
Trivedi S, Zeier M, Reiser J. Role of podocytes in lupus nephritis. Nephrol Dial 
Transplant. 2009;24:3607-12. 
9. 
Mathieson PW. Proteinuria and immunity - an overstated relationship? N Engl J Med. 
2008 Dec 4;359(23):2492-4. 
10. 
Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV 
lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008 Oct; 19(10):2001-
10. Epub 2008 Jul 2. 
11. 
Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus 
nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 
2009;19:606-15. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 91 of 114 
 
12. 
Cortés-Hernández J, Torres-Salido MT, Medrano AS, Tarrés MV, Ordi-Ros J. Long-
term outcomes-mycophenolate mofetil treatment for lupus nephritis with addition of 
tacrolimus for resistant cases. Nephrol Dial Transplant. 2010; 25:3939-48. Epub 2010 
Jun 10. 
13. 
Szeto C-C, Kwan BC-H, Lai FM-M, Tam L-S, Li EK-M, Chow K-M, et al. Tacrolimus 
for the treatment of systemic lupus erythematosus with pure class V nephritis. 
Rheumatology. 2008;47:1678-81. 
14. 
Uchino A, Tsukamoto H, Nakashima H, Yoshizawa S, Furugo I, Mitoma H, et al. 
Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp 
Rheumatol. 2010 Jan-Feb;28(1):6-12. 
15. 
Tanaka H, Oki E, Tsugawa K, Nonaka K, Suzuki K, Ito E. Effective treatment of young 
subjects with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a 
single daily dose: an open-label pilot study. Lupus. 2007;16(11):896-900. 
16. 
Asamiya Y, Uchida K, Otsubo S, Takei T, Nitta K. Clinical assessment of tacrolimus 
therapy in lupus nephritis: one-year follow-up study in a single center. Nephron Clin 
Pract. 2009;113(4):c330-6. Epub 2009 Sep 3. 
17. 
Tse KC, Lam MF, Tang SCW, Tang CSO, Chan TM. A pilot study on tacrolimus 
treatment in membranous or quiescent lupus nephritis with proteinuria resistant to 
angiotensin inhibition or blockade. Lupus. 2007;16(1):46-51. 
18. 
Lanata CM, Mahmood T, Fine DM, Petri M. Combination therapy of mycophenolate 
mofetil and tacrolimus in lupus nephritis. Lupus. 2010 Jul;19(8):935-40. Epub 2010 
Apr 13. 
19. 
Lee T, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, et al. Tacrolimus is an alternative 
therapeutic option for the treatment of refractory lupus nephritis. Lupus. 
2010 Jul;19(8):974-80. 
20. 
KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, 
Classification, and Stratification, 2002.  
http://www2.kidney.org/professionals/KDOQI/guidelines_ckd/p4_class_g1.htm. 
Accessed 2 September 2014. 
21. 
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. 
Biometrika. 1988;74(4):800-2. 
22. 
World Medical Association Declaration of Helsinki. Ethical principles for medical 
research involving human subjects. 64th WMA General Asssembly, Fortaleza, Brazil. 
October 2013. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 92 of 114 
 
23. 
ICH Harmonised Tripartite Guideline.: Guideline for good clinical practice. E6 (R1) 
1996 Jun 10. 
24. 
PhRMA principles and guidelines: public disclosure of clinical trial results. 
Pharmaceutical Research and Manufacturers of America [Internet]. 2009 [cited 2009]. 
Available from: http://www.phrma.org/principles_and_guidelines. 
25. 
International Committee of Medical Journal Editors [Internet]. Uniform requirements 
for manuscripts submitted to biomedical journals: writing and editing for biomedical 
publication [updated 2010 Apr]. Available from: http://www.icmje.org. 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 93 of 114 
 
Appendix 1 
Drug Therapy for the Treatment of Hypertension 
Antihypertensive drug therapy for subjects who either have hypertension at screening or who 
develop hypertension while on study treatment may include the following: 
• Dihydropyridine calcium channel blockers (e.g., amlodipine, nifedipine) 
• Alpha-1-adrenergic blocking agents (e.g., doxazosin) 
• Alpha-beta-blockers (e.g., carvedilol, labetalol) 
• Thiazide diuretics (e.g., chlorthalidone or hydrochlorothiazide) 
Excluded Drugs: While the ARBs and ACE inhibitors may also be effective in calcineurin 
inhibitor-associated hypertension, their dose adjustment or commencement is not permitted in 
this trial (see Section 7.8.1, Prohibited Medications). 
Recommended First and Second Line Therapies for Treatment of Hypertension 
Titrate the following according to the timeframe given in the respective drug label: 
First Line - select from one of the following: 
• Amlodipine, 5 mg daily to achieve BP <140/90 mmHg; titrate to 10 mg daily if 
satisfactory results not obtained within 2 weeks 
• Nifedipine XL, 30 mg daily; titrate to 60 mg and possibly 90 mg daily within 2 weeks 
• 12.5 to 25 mg/day of chlorthalidone or hydrochlorothiazide 
Second Line - may add from among the following to the first line therapy if a partial response 
is obtained: 
• Labetalol, 100 mg BID; titrate to 200 mg BID, then 300 mg BID 
Note: If the BP remains uncontrolled with the above-referenced maximum doses of first and 
second-line antihypertensive therapies, reduction of study treatment dose may be considered 
or it may be decided to discontinue study treatment and utilize antihypertensive therapies to 
achieve control of BP. 
If at any time, in the judgment of the treating physician in consultation with the Medical 
Monitor, the response to treatment is inadequate, the study treatment may be 
discontinued. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 94 of 114 
 
Appendix 2 
Measurement of Blood Pressure  
1. Whenever possible, BP measurements should be undertaken by the same study site 
personnel at each clinic visit. 
2. Whenever possible, the BP determinations should be undertaken at approximately the same 
time of day for each study visit and at the same time in relations to prior study treatment 
ingestion. 
3. The measurements should be undertaken prior to blood collection. 
4. Prior to measuring BP, the study subject should be seated in a quiet room for at least 
5 minutes, in a chair with his/her back supported and feet comfortably resting on the floor. 
5. Due to the likelihood each arm can have a slightly different BP, it is strongly encouraged 
to use the same arm that was selected at screening for all measurements, supported at heart 
level. 
6. No restrictive clothing should encircle the arm in which BP measurements are determined. 
7. An appropriately sized cuff will be required wherein the cuff bladder encircles at least 80% 
of the upper portion of the arm. 
8. Three serial BP readings will be undertaken with a minimum of 2 minutes between 
readings and with the cuff fully deflated between each determination. 
9. The mean of the second and third of these 3 readings will be used as the study day BP 
value. 
10. All measurements, along with the calculated mean value, will be recorded in the source 
documents. The mean of the second and third readings will be calculated within the EDC 
as the study day result. 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 95 of 114 
 
Appendix 3 
International Society of Nephrology and the Renal Pathology Society 
(ISN/RPS) 2003 Classification of Lupus Nephritis 
Class I 
Minimal mesangial lupus nephritis 
Normal glomeruli by light microscopy, but mesangial immune deposits by 
immunofluorescence  
Class II 
Mesangial proliferative lupus nephritis 
Purely mesangial hypercellularity of any degree or mesangial matrix 
expansion by light microscopy, with mesangial immune deposits 
May be a few isolated subephithelial or subendothelial deposits visible by 
immunofluorescence or electron microscopy, but not by light microscopy 
Class III 
Focal lupus nephritisª 
Active or inactive focal, segmental or global endo- or extracapillary 
glomerulonephritis involving <50% of all glomeruli, typically with focal 
subendothelial immune deposits, with or without mesangial alterations 
Class III (A) 
Active lesions: focal proliferative lupus nephritis 
Class III (A/C) 
Active and chronic lesions: focal proliferative and sclerosing lupus nephritis 
Class III (C) 
Chronic inactive lesions with glomerular scars: focal sclerosing lupus 
nephritis 
Class IV 
Diffuse lupus nephritisb 
Active or inactive diffuse, segmental or global endo- or extracapillary 
glomerulonephritis involving ≥50% of all glomeruli, typically with diffuse 
subendothelial immune deposits, with or without mesangial alterations. This 
class is divided into diffuse segmental (IV-S) lupus nephritis when ≥50% of 
the involved glomeruli have segmental lesions, and diffuse global (IV-G) 
lupus nephritis when ≥50% of the involved glomeruli have global lesions. 
Segmental is defined as a glomerular lesion that involves less than half of the 
glomerular tuft. This class includes cases with diffuse wire loop deposits but 
with little or no glomerular proliferation.  
Class IV-S (A) 
Active lesions: diffuse segmental proliferative lupus nephritis 
Class IV-G (A) 
Active lesions: diffuse global proliferative lupus nephritis 
Class IV-S (A/C) 
Active and chronic lesions: diffuse segmental proliferative and sclerosing 
lupus nephritis 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 96 of 114 
 
Class IV-G (A/C) 
Active and chronic lesions: diffuse global proliferative and sclerosing lupus 
nephritis 
Class IV-S (C) 
Chronic inactive lesions with scars: diffuse segmental sclerosing lupus 
nephritis 
Class IV-G (C) 
Chronic inactive lesions with scars: diffuse global sclerosing lupus nephritis 
Class V 
Membranous lupus nephritis 
Global or segmental subephithelial immune deposits or their morphologic 
sequelae by light microscopy and by immunofluorescence or electron 
microscopy, with or without mesangial alterations 
Class V lupus nephritis may occur in combination with class II or IV in 
which case both will be diagnosed 
Class V lupus nephritis show advanced sclerosis 
Class VI 
Advanced sclerosis lupus nephritis 
≥90% of glomeruli globally sclerosed without residual activity 
 
a Indicate the proportion of glomeruli with active and with sclerotic lesions. 
b Indicate the proportion of glomeruli with fibrinoid necrosis and/or cellular crescents. 
Indicate and grade (mild, moderate, severe) tubular atrophy, interstitial inflammation and fibrosis, 
severity of arteriosclerosis or other vascular lesions. 
 
1. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The 
classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 
2004;65:521-30. 
2. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The 
classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 
2004;15:241-50. 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 97 of 114 
 
Appendix 4 
Conversion Table for Oral Corticosteroids 
Compound 
Equivalent Potency (mg) 
Prednisone 
5 
Prednisolone 
5 
Cortisone 
25 
Hydrocortisone (cortisol) 
20 
Methylprednisolone 
4 
Triamcinolone 
4 
Dexamethasone 
0.75 
 
i.e., 
1 mg prednisone = 1 mg prednisolone 
1 mg prednisone = 5 mg cortisone 
1 mg prednisone = 4 mg hydrocortisone (cortisol) 
1 mg prednisone = 0.8 mg methylprednisolone 
1 mg prednisone = 0.8 mg triamcinolone 
1 mg prednisone = 0.15 mg dexamethasone 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 98 of 114 
 
Appendix 5 
1997 Update of the 1982 American College of Rheumatology Revised 
Criteria for the Classification of Systemic Lupus Erythematosus 
 
Four or More of: 
Criterion 
Definition 
1. Malar rash 
Fixed erythema, flat or raised, over the malar eminences, tending 
to spare the nasolabial folds 
2. Discoid rash 
Erythematous raised patches with adherent keratotic scaling and 
follicular plugging; atrophic scarring may occur in older lesions 
3. Photosensitivity 
Skin rash as a result of unusual reaction to sunlight, by patient 
history or physician observation 
4. Oral ulcers 
Oral or nasopharyngeal ulceration, usually painless, observed by 
physician  
5. Arthritis 
Nonerosive arthritis involving 2 or more peripheral joints, 
characterized by tenderness, swelling, or effusion 
6. Serositis 
a) Pleuritis--convincing history of pleuritic pain or rubbing heard 
by a physician or evidence of pleural effusion  
OR 
b) Pericarditis--documented by ECG or rub or evidence of 
pericardial effusion 
7. Renal disorder 
a) Persistent proteinuria greater than 0.5 grams per day (or 
0.5 mg/mg by UPCR) or greater than 3+ if quantitation not 
performed  
OR 
b) Cellular casts--may be red cell, hemoglobin, granular, tubular, 
or mixed 
8. Neurologic 
disorder 
a) Seizures--in the absence of offending drugs or known metabolic 
derangements; e.g., uremia, ketoacidosis, or electrolyte imbalance  
OR 
b) Psychosis--in the absence of offending drugs or known 
metabolic derangements, e.g., uremia, ketoacidosis, or electrolyte 
imbalance 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 99 of 114 
 
Four or More of: 
Criterion 
Definition 
9. Hematologic 
disorder 
a) Hemolytic anemia--with reticulocytosis  
OR 
b) Leukopenia--less than 4,000/mm3 total on 2 or more occasions 
OR 
c) Lyphopenia--less than 1,500/mm3 on 2 or more occasions 
OR 
d) Thrombocytopenia--less than 100,000/mm3 in the absence of 
offending drugs  
10. Immunologic 
disorder 
a) Anti-dsDNA: antibody to native dsDNA in abnormal titer 
OR 
b) Anti-Sm: presence of antibody to Sm nuclear antigen 
OR 
c) Positive finding of antiphospholipid antibodies based on 1) an 
abnormal serum level of IgG or IgM anticardiolipin antibodies, 2) 
a positive test result for lupus anticoagulant using a standard 
method, or 3) a false-positive serologic test for syphilis known to 
be positive for at least 6 months and confirmed by Treponema 
pallidum immobilization or fluorescent treponemal antibody 
absorption test 
11. Antinuclear 
antibody 
An abnormal titer of antinuclear antibody by immunofluorescence 
or an equivalent assay at any point in time and in the absence of 
drugs known to be associated with "drug-induced lupus" 
syndrome  
Abbreviation: ECG = Electrocardiogram. 
Sources: Hochberg MC, MD, MPH for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Tan 
EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria 
for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7. 
 
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus 
erythematosus [letter]. Arthritis Rheum 1997;40:1725. 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 100 of 114 
 
Appendix 6 
Systemic Lupus Erythematosus Disease Activity Measure 
(SELENA-SLEDAI) 
Descriptor 
Definition 
Points 
Seizure 
Recent onset. Exclude metabolic, infectious or drug 
causes. 
8 
Psychosis 
Altered ability to function in normal activity due to 
severe disturbance in the perception of reality. Include 
hallucinations, incoherence, marked loose associations, 
impoverished thought content, marked illogical thinking, 
bizarre, disorganized or catatonic behavior. Exclude 
uremia and drug causes. 
8 
Organic brain 
syndrome 
Altered mental function with impaired orientation, 
memory or other intellectual function with rapid onset 
and fluctuating clinical features. Include clouding of 
consciousness with reduced capacity to focus and 
inability to sustain attention to environment plus at least 
2 of the following: perceptual disturbance, incoherent 
speech, insomnia or daytime drowsiness, or increased or 
decreased psychomotor activity. Exclude metabolic, 
infectious or drug causes. 
8 
Visual disturbance 
Retinal changes of SLE. Include cytoid bodies, retinal 
hemorrhages, serous exudate or hemorrhages in the 
choroid, or optic neuritis. Exclude hypertension, 
infectious or drug causes. 
8 
Cranial nerve 
disorder 
New onset of sensory or motor neuropathy involving 
cranial nerves. 
8 
Lupus headache 
Severe persistent headache; may be migrainous but must 
be nonresponsive to narcotic analgesia. 
8 
Cerebrovascular 
accident  
New onset of cerebrovascular accident(s). Exclude 
arteriosclerosis. 
8 
Vasculitis 
Ulceration, gangrene, tender finger nodules, periungual 
infarction, splinter hemorrhages, or biopsy or angiogram 
proof of vasculitis. 
8 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 101 of 114 
 
Descriptor 
Definition 
Points 
Arthritis 
More than 2 joints with pain and signs of inflammation 
(i.e., tenderness, swelling, or effusion). 
4 
Myositis 
Proximal muscle aching or weakness associated with 
elevated creatine phosphokinase or aldolase, or 
electromyogram changes, or a biopsy showing myositis. 
4 
Urinary casts 
Heme-granular or RBC casts. 
4 
Hematuria 
>5 red blood cells per high powered field. Exclude 
stone, infection or other causes. 
4 
Proteinuria 
>0.5 g per 24 hours or 0.5 mg/mg UPCR by FMV. New 
onset or recent increase of more than 0.5 g per 24 hours. 
4 
Pyuria 
>5 white blood cells per high power field. Exclude 
infection. 
4 
New rash 
New onset or recurrence of inflammatory type rash. 
2 
Alopecia 
New onset or recurrence of abnormal patchy or diffuse 
loss of hair. 
2 
Mucosal ulcers 
New onset or recurrence of oral or nasal ulcerations. 
2 
Pleurisy 
Pleuritic chest pain with pleural rub or effusion or 
pleural thickening. 
2 
Pericarditis 
Pericardial pain with at least 1 one of the following: rub, 
effusion or ECG confirmation. 
2 
Low complement 
Decrease in CH50, C3 or C4 below the lower limit of 
normal for testing laboratory. 
2 
Increased DNA 
binding 
>25% binding by Farr assay or above normal range for 
testing laboratory. 
2 
Fever 
>38°C. Exclude infectious cause. 
1 
Thrombocytopenia 
<100,000 platelets per mm3. 
1 
Leukopenia 
<3,000 white blood cells per mm3. Exclude drug causes. 
1 
Abbreviations: ECG = Electrocardiogram; RBC = Red blood cells; SLE = Systemic lupus erythematosus.  
Source: Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of 
the SLEDAI: a disease activity index for lupus subjects. Arthritis Rheum. 1992;35:S630-40. 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 102 of 114 
 
Appendix 7 
Expanded List of Allowed Concomitant Medications 
• Prophylactic therapy for steroid-induced bone loss (calcium with Vitamin D and/or a 
bisphosphonate). 
• Low dose aspirin is allowed for cardiovascular prophylaxis. 
• Minor GI AEs (such as nausea, vomiting and diarrhea) may be treated symptomatically 
(e.g., with loperamide for diarrhea or standard anti-emetics such as metoclopramide or 
domperidone for nausea and vomiting). Proton pump inhibitors or ranitidine are 
permitted for dyspepsia or gastric protection. Magnesium or aluminum containing 
antacids may be used, but should not be taken at the same time as study treatment; such 
antacids, if required, should be taken either 1 hour before or 2 hours after study 
treatment. 
• Amphotericin or oral nystatin are permitted as infective prophylaxis against fungal 
infections, and low-dose sulfamethoxazole/trimethoprim is permitted as prophylaxis 
against Pneumocystis carinii pneumonia. 
• Granulocyte colony stimulating factor is allowed to manage neutropenia in the presence 
of major infection (i.e., infections requiring IV antibiotics). 
• Oral or IV iron preparations for iron deficiency and/or anemia. 
• Erythropoietin is permitted for treatment of severe anemia (hemoglobin <10 mg/dL). 
• Cytomegalovirus prophylaxis is permitted for example with oral valganciclovir. 
• Acute intermittent administration of NSAIDs for not greater than 7 consecutive days is 
permitted. 
• Lipid-lowering therapies (e.g., statins) will be used as clinically indicated. 
• Antimalarials should be prescribed when clinically indicated. 
• Angiotensin-converting enzyme inhibitors, ARBs, and aliskerin and other therapies are 
recommended, as per standard guidelines but if used their dose must be stable 
throughout the study. In addition subjects must be on a stable dose of ACE inhibitors 
or ARBs for 4 weeks prior to enrollment.  
• In the case of uncontrolled hypertension (systolic BP >165 mmHg or 
diastolic >105 mmHg on 2 successive measurements), the addition of a diuretic or 
calcium channel blocker only are permitted, together with dose decreases or 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 103 of 114 
 
interruption of study treatment per the instructions in Section 7.9, Increased Blood 
Pressure. 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 104 of 114 
 
Appendix 8 
Summary of Treatment and Food Restrictions 
Treatment 
Washout Period 
During Treatment 
Reason 
Immunosuppressants other 
than those allowed by 
protocol 
30 days 
Prohibited 
Interferes with 
study efficacy 
endpoints 
Aminoglycosides 
Amphotericin B 
Melphalan 
Ketoconazole 
Rifampin 
14 days 
Prohibited 
May potentiate 
toxicity 
NSAIDs chronic dosing 
(>7 consecutive days) 
Prohibited 
Prohibited 
May potentiate 
nephrotoxicity 
P-gp substrates 
To be monitored 
To be monitored 
Drug-drug 
interaction 
P-gp inhibitors 
To be discussed with 
Medical Monitor 
To be discussed with 
Medical Monitor 
Drug-drug 
interaction 
Androgenic steroids 
Cimetidine 
Fluconazole, itraconazole 
Macrolide antibiotics 
(azithromycin, 
clarithromycin, 
erythromycin) 
Metoclopramide 
Barbiturates and derivatives 
Carbamazepine 
Octreotide acetate 
Phenytoin 
Sulfadimidine (intravenous) 
Theophylline 
To be discussed with 
Medical Monitor 
To be discussed with 
Medical Monitor 
Drugs interfering 
with Orelvo 
metabolism 
ACE inhibitors and ARBs 
No change or introduction 
during screening 
Change or 
commencement 
prohibited 
Interfere with 
primary endpoint 
assessment 
Foods 
Grapefruit and grapefruit 
juice 
 
24 hours 
 
Prohibited 
 
May affect the 
metabolism of 
Orelvo 
Abbreviations: ACE = Angiotensin converting enzyme; ARB = Angiotensin receptor blocker; NSAID = Non-steroidal anti-inflammatory 
drug; P-gp = P-glycoprotein. 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 105 of 114 
 
Appendix 9 
Short Form Health Survey (SF-36) HRQoL Assessment 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 106 of 114 
 

 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 107 of 114 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 108 of 114 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 109 of 114 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 110 of 114 
 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 111 of 114 
 
Appendix 10 LupusPRO (v1.7) HRQoL Assessment  
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 112 of 114 
 
 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 113 of 114 
 

 
 
AURORA 1 (AUR-VCS-2016-01), Version 2.0 (Amendment 1) 
Confidential 
04 May 2017 
Page 114 of 114